Omega Healthcare Investors (OHI) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 02, 2017
Document And Entity Information [Line Items]
Entity Registrant Name	OMEGA HEALTHCARE INVESTORS INC
Entity Central Index Key	888,491
Trading Symbol	ohi
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock Shares Outstanding		197,241,081
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
OHI Healthcare Properties Holdco, Inc.
Document And Entity Information [Line Items]
Entity Registrant Name	OHI Healthcare Properties Holdco, Inc.
Entity Central Index Key	1,639,311
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock Shares Outstanding		1,000
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
OHI Healthcare Properties Limited Partnership
Document And Entity Information [Line Items]
Entity Registrant Name	OHI Healthcare Properties Limited Partnership
Entity Central Index Key	1,639,315
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock Shares Outstanding		0
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Real estate properties
Real estate investments (see Note 2)	$ 7,730,199	$ 7,566,358
Less accumulated depreciation	(1,366,376)	(1,240,336)
Real estate investments - net	6,363,823	6,326,022
Investments in direct financing leases - net	582,307	601,938
Mortgage notes receivable - net	662,709	639,343
Total	7,608,839	7,567,303
Other investments - net	278,985	256,846
Investment in unconsolidated joint venture	38,968	48,776
Assets held for sale - net	18,889	52,868
Total investments	7,945,681	7,925,793
Cash and cash equivalents	21,031	93,687
Restricted cash	12,203	13,589
Accounts receivable - net	288,686	240,035
Goodwill	644,184	643,474
Other assets	34,869	32,682
Total assets	8,946,654	8,949,260
LIABILITIES AND OWNERS' EQUITY
Revolving line of credit	155,000	190,000
Term loans - net	899,292	1,094,343
Secured borrowings - net	53,737	54,365
Unsecured borrowings - net	3,321,858	3,028,146
Accrued expenses and other liabilities	323,543	360,514
Deferred income taxes	17,714	9,906
Total liabilities	4,771,144	4,737,274
Equity:
Common stock $.10 par value authorized - 350,000 shares, issued and outstanding - 197,224 shares as of June 30, 2017 and 196,142 as of December 31, 2016	19,722	19,614
Common stock - additional paid-in capital	4,896,076	4,861,408
Cumulative net earnings	1,908,634	1,738,937
Cumulative dividends paid	(2,954,230)	(2,707,387)
Accumulated other comprehensive loss	(41,903)	(53,827)
Total stockholders' equity	3,828,299	3,858,745
Noncontrolling interest	347,211	353,241
Total equity	4,175,510	4,211,986
Owners' Equity:
Total liabilities and equity	8,946,654	8,949,260
OHI Healthcare Properties Holdco, Inc.
Real estate properties
Real estate investments (see Note 2)	7,730,199	7,566,358
Less accumulated depreciation	(1,366,376)	(1,240,336)
Real estate investments - net	6,363,823	6,326,022
Investments in direct financing leases - net	582,307	601,938
Mortgage notes receivable - net	662,709	639,343
Total	7,608,839	7,567,303
Other investments - net	278,985	256,846
Investment in unconsolidated joint venture	38,968	48,776
Assets held for sale - net	18,889	52,868
Total investments	7,945,681	7,925,793
Cash and cash equivalents	21,031	93,687
Restricted cash	12,203	13,589
Accounts receivable - net	288,686	240,035
Goodwill	644,184	643,474
Other assets	34,869	32,682
Total assets	8,946,654	8,949,260
LIABILITIES AND OWNERS' EQUITY
Term loans - net	99,372	100,000
Secured borrowings - net	53,737	54,365
Accrued expenses and other liabilities	267,346	302,959
Deferred income taxes	17,714	9,906
Intercompany loans payable	4,332,975	4,270,044
Total liabilities	4,771,144	4,737,274
Equity:
Common stock - additional paid-in capital	923,218	923,218
Cumulative net earnings	163,808	126,187
Cumulative dividends paid	(229,930)	(175,289)
Accumulated other comprehensive loss	(9,797)	(12,439)
Total stockholders' equity	847,299	861,677
Noncontrolling interest	3,328,211	3,350,309
Total equity	4,175,510	4,211,986
Owners' Equity:
Total liabilities and equity	8,946,654	8,949,260
OHI Healthcare Properties Limited Partnership
Real estate properties
Real estate investments (see Note 2)	7,730,199	7,566,358
Less accumulated depreciation	(1,366,376)	(1,240,336)
Real estate investments - net	6,363,823	6,326,022
Investments in direct financing leases - net	582,307	601,938
Mortgage notes receivable - net	662,709	639,343
Total	7,608,839	7,567,303
Other investments - net	278,985	256,846
Investment in unconsolidated joint venture	38,968	48,776
Assets held for sale - net	18,889	52,868
Total investments	7,945,681	7,925,793
Cash and cash equivalents	21,031	93,687
Restricted cash	12,203	13,589
Accounts receivable - net	288,686	240,035
Goodwill	644,184	643,474
Other assets	34,869	32,682
Total assets	8,946,654	8,949,260
LIABILITIES AND OWNERS' EQUITY
Term loans - net	99,372	100,000
Secured borrowings - net	53,737	54,365
Accrued expenses and other liabilities	267,346	302,959
Deferred income taxes	17,714	9,906
Intercompany loans payable	4,332,975	4,270,044
Total liabilities	4,771,144	4,737,274
Equity:
Accumulated other comprehensive loss	(43,913)
Owners' Equity:
General partners' equity	3,828,299	3,858,745
Limited partners' equity	347,211	353,241
Total owners' equity	4,175,510	4,211,986
Total liabilities and equity	$ 8,946,654	$ 8,949,260

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares shares in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized	350,000	350,000
Common stock, shares issued	197,224	196,142
Common stock, shares outstanding	197,224	196,142

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue
Rental income	$ 193,997	$ 186,454	$ 386,534	$ 363,157
Income from direct financing leases	15,462	15,521	31,108	30,963
Mortgage interest income	16,297	21,371	32,253	37,977
Other investment income - net	7,278	4,982	14,192	8,413
Miscellaneous income	2,763	496	3,454	1,193
Total operating revenues	235,797	228,824	467,541	441,703
Expenses
Depreciation and amortization	70,350	65,505	140,343	127,938
General and administrative	11,541	11,832	24,065	22,287
Acquisition costs	19	3,504	(22)	7,275
Impairment loss on real estate properties	10,135	6,893	17,773	41,451
Provision for uncollectible accounts	2,673	(1,154)	5,077	3,970
Total operating expenses	94,718	86,580	187,236	202,921
Income before other income and expense	141,079	142,244	280,305	238,782
Other income (expense)
Interest income	254	4	258	12
Interest expense	(48,085)	(39,651)	(93,126)	(76,873)
Interest - amortization of deferred financing costs	(2,543)	(2,210)	(5,045)	(4,342)
Interest - refinancing costs	(21,965)		(21,965)	(298)
Contractual settlement			10,412
Realized gain (loss) on foreign exchange	79		140	(22)
Total other expense	(72,260)	(41,857)	(109,326)	(81,523)
Income before (loss) gain on assets sold	68,819	100,387	170,979	157,259
(Loss) gain on assets sold - net	(622)	13,221	6,798	14,792
Income from continuing operations	68,197	113,608	177,777	172,051
Income taxes	(591)	(454)	(1,691)	(701)
Income from unconsolidated joint venture	551		1,183
Net income	68,157	113,154	177,269	171,350
Net income attributable to noncontrolling interest	(2,900)	(5,102)	(7,572)	(7,743)
Net income available to common stockholders	$ 65,257	$ 108,052	$ 169,697	$ 163,607
Basic:
Net income available to common stockholders	$ 0.33	$ 0.57	$ 0.86	$ 0.87
Diluted:
Net income	0.33	0.57	0.86	0.86
Diluted:
Dividends declared per common share (in dollars per share)	$ 0.63	$ 0.58	$ 1.25	$ 1.15
Weighted-average shares outstanding, basic (in shares)	197,433	188,981	197,223	188,604
Weighted-average shares outstanding, diluted (in shares)	206,672	199,157	206,423	198,754
OHI Healthcare Properties Holdco, Inc.
Revenue
Rental income	$ 193,997	$ 186,454	$ 386,534	$ 363,157
Income from direct financing leases	15,462	15,521	31,108	30,963
Mortgage interest income	16,297	21,371	32,253	37,977
Other investment income - net	7,278	4,982	14,192	8,413
Miscellaneous income	2,763	496	3,454	1,193
Total operating revenues	235,797	228,824	467,541	441,703
Expenses
Depreciation and amortization	70,350	65,505	140,343	127,938
General and administrative	11,541	11,832	24,065	22,287
Acquisition costs	19	3,504	(22)	7,275
Impairment loss on real estate properties	10,135	6,893	17,773	41,451
Provision for uncollectible accounts	2,673	(1,154)	5,077	3,970
Total operating expenses	94,718	86,580	187,236	202,921
Income before other income and expense	141,079	142,244	280,305	238,782
Other income (expense)
Interest income	254	4	258	12
Interest expense	(48,085)	(39,651)	(93,126)	(76,873)
Interest - amortization of deferred financing costs	(2,543)	(2,210)	(5,045)	(4,342)
Interest - refinancing costs	(21,965)		(21,965)	(298)
Contractual settlement			10,412
Realized gain (loss) on foreign exchange	79		140	(22)
Total other expense	(72,260)	(41,857)	(109,326)	(81,523)
Income before (loss) gain on assets sold	68,819	100,387	170,979	157,259
(Loss) gain on assets sold - net	(622)	13,221	6,798	14,792
Income from continuing operations	68,197	113,608	177,777	172,051
Income taxes	(591)	(454)	(1,691)	(701)
Income from unconsolidated joint venture	551		1,183
Net income	68,157	113,154	177,269	171,350
Net income attributable to noncontrolling interest	(53,709)	(88,160)	(139,648)	(133,455)
Net income available to common stockholders	14,448	24,994	37,621	37,895
OHI Healthcare Properties Limited Partnership
Revenue
Rental income	193,997	186,454	386,534	363,157
Income from direct financing leases	15,462	15,521	31,108	30,963
Mortgage interest income	16,297	21,371	32,253	37,977
Other investment income - net	7,278	4,982	14,192	8,413
Miscellaneous income	2,763	496	3,454	1,193
Total operating revenues	235,797	228,824	467,541	441,703
Expenses
Depreciation and amortization	70,350	65,505	140,343	127,938
General and administrative	11,541	11,832	24,065	22,287
Acquisition costs	19	3,504	(22)	7,275
Impairment loss on real estate properties	10,135	6,893	17,773	41,451
Provision for uncollectible accounts	2,673	(1,154)	5,077	3,970
Total operating expenses	94,718	86,580	187,236	202,921
Income before other income and expense	141,079	142,244	280,305	238,782
Other income (expense)
Interest income	254	4	258	12
Interest expense	(48,085)	(39,651)	(93,126)	(76,873)
Interest - amortization of deferred financing costs	(2,543)	(2,210)	(5,045)	(4,342)
Interest - refinancing costs	(21,965)		(21,965)	(298)
Contractual settlement			10,412
Realized gain (loss) on foreign exchange	79		140	(22)
Total other expense	(72,260)	(41,857)	(109,326)	(81,523)
Income before (loss) gain on assets sold	68,819	100,387	170,979	157,259
(Loss) gain on assets sold - net	(622)	13,221	6,798	14,792
Income from continuing operations	68,197	113,608	177,777	172,051
Income taxes	(591)	(454)	(1,691)	(701)
Income from unconsolidated joint venture	551		1,183
Net income	$ 68,157	$ 113,154	$ 177,269	$ 171,350
Basic:
Net income (in dollars per share)	$ 0.33	$ 0.57	$ 0.86	$ 0.87
Diluted:
Net income (in dollars per shares)	0.33	0.57	0.86	0.86
Dividends declared per common share (in dollars per share)	$ 0.63	$ 0.58	$ 1.25	$ 1.15
Weighted-average Omega OP Units outstanding, basic (in shares)	206,205	197,903	206,016	197,539
Weighted-average Omega OP Units outstanding, diluted (in shares)	206,672	199,157	206,423	198,754

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income	$ 68,157	$ 113,154	$ 177,269	$ 171,350
Other comprehensive income (loss)
Foreign currency translation	10,274	(21,836)	14,608	(26,566)
Derivative instruments	(3,407)	(4,198)	(2,153)	(13,074)
Total other comprehensive income (loss)	6,867	(26,034)	12,455	(39,640)
Comprehensive income	75,024	87,120	189,724	131,710
Comprehensive income attributable to noncontrolling interest	(3,192)	(3,928)	(8,103)	(5,953)
Comprehensive income attributable to common stockholders	71,832	83,192	181,621	125,757
OHI Healthcare Properties Holdco, Inc.
Net income	68,157	113,154	177,269	171,350
Other comprehensive income (loss)
Foreign currency translation	10,274	(21,836)	14,608	(26,566)
Derivative instruments	(3,407)	(4,198)	(2,153)	(13,074)
Total other comprehensive income (loss)	6,867	(26,034)	12,455	(39,640)
Comprehensive income	75,024	87,120	189,724	131,710
Comprehensive income attributable to noncontrolling interest	(59,120)	(67,877)	(149,460)	(102,581)
Comprehensive income attributable to common stockholders	15,904	19,243	40,264	29,129
OHI Healthcare Properties Limited Partnership
Net income	68,157	113,154	177,269	171,350
Other comprehensive income (loss)
Foreign currency translation	10,274	(21,836)	14,608	(26,566)
Derivative instruments	(3,407)	(4,198)	(2,153)	(13,074)
Total other comprehensive income (loss)	6,867	(26,034)	12,455	(39,640)
Comprehensive income	$ 75,024	$ 87,120	$ 189,724	$ 131,710

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($) shares in Thousands, $ in Thousands	Common Stock Par Value	Additional Paid-in Capital	Cumulative Net Earnings	Cumulative Dividends	Accumulated Other Comprehensive Loss	Total Stockholders' Equity	Noncontrolling Interest	Total	OHI Healthcare Properties Holdco, Inc.Additional Paid-in Capital	OHI Healthcare Properties Holdco, Inc.Cumulative Net Earnings	OHI Healthcare Properties Holdco, Inc.Cumulative Dividends	OHI Healthcare Properties Holdco, Inc.Accumulated Other Comprehensive Loss	OHI Healthcare Properties Holdco, Inc.Total Stockholders' Equity	OHI Healthcare Properties Holdco, Inc.Noncontrolling Interest	OHI Healthcare Properties Holdco, Inc.	OHI Healthcare Properties Limited PartnershipGeneral Partners' Omega OP Units	OHI Healthcare Properties Limited PartnershipLimited Partners' Omega OP Units	OHI Healthcare Properties Limited Partnership
Balance (196,142 common shares & 8,862 Omega OP Units) at Dec. 31, 2016	$ 19,614	$ 4,861,408	$ 1,738,937	$ (2,707,387)	$ (53,827)	$ 3,858,745	$ 353,241	$ 4,211,986	$ 923,218	$ 126,187	$ (175,289)	$ (12,439)	$ 861,677	$ 3,350,309	$ 4,211,986
Balance at Dec. 31, 2016																$ 3,858,745	$ 353,241	$ 4,211,986
Balance (in units) at Dec. 31, 2016																196,142	8,862	205,004
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Grant of restricted stock to company directors (32 shares at $31.23 per share)	3	(3)
Stock-based compensation expense		7,478				7,478		7,478
Vesting/exercising of equity compensation plan, net of tax withholdings (114 shares)	11	(2,131)				(2,120)		(2,120)
Dividend reinvestment and stock purchase plan (614 shares at an average of $32.11 per share)	61	19,660				19,721		19,721
Grant of stock as payment of directors fees (5 shares at an average of $32.18 per share)	1	149				150		150
Deferred compensation directors		(29)				(29)		(29)
Equity Shelf Program (228 shares at $29.17 per share, net of issuance costs)	23	6,611				6,634		6,634
Common dividends declared ($1.25 per share)				(246,843)		(246,843)		(246,843)
Conversion of Omega OP Units to common stock (89 shares at $32.91 per share)	9	2,933				2,942		2,942
Redemption of Omega OP Units (90 units)							(2,990)	(2,990)
Omega OP Units distributions							(11,143)	(11,143)
Contributions from partners																$ 34,776		$ 34,776
Contributions from partners (in shares)																1,082		1,082
Omega OP Unit redemptions																	$ (2,990)	$ (2,990)
Omega OP Unit redemptions (in shares)																	(90)	(90)
Contributions														34,776	34,776
Distributions											(54,641)		(54,641)	(206,335)	(260,976)	$ (246,843)	$ (11,143)	$ (257,986)
Foreign currency translation					13,986	13,986	622	14,608				3,098	3,098	11,510	14,608	13,986	622	14,608
Derivative instruments					(2,062)	(2,062)	(91)	(2,153)				(456)	(456)	(1,697)	(2,153)	(2,062)	(91)	(2,153)
Net income			169,697			169,697	7,572	177,269		37,621			37,621	139,648	177,269	169,697	7,572	177,269
Balance (197,224 shares & 8,772 Omega OP Units) at Jun. 30, 2017	$ 19,722	$ 4,896,076	$ 1,908,634	$ (2,954,230)	$ (41,903)	$ 3,828,299	$ 347,211	$ 4,175,510	$ 923,218	$ 163,808	$ (229,930)	$ (9,797)	$ 847,299	$ 3,328,211	$ 4,175,510
Balance at Jun. 30, 2017																$ 3,828,299	$ 347,211	$ 4,175,510
Balance (in units) at Jun. 30, 2017																197,224	8,772	205,996

CONSOLIDATED STATEMENT OF CHAN7

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) (Parentheticals) - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Balance (in shares)	196,142
Grant of restricted stock (in shares)	32
Grant of restricted stock (in dollars per share)	$ 31.23
Vesting/exercising of equity compensation plan (in shares)	114
Shares issued under dividend reinvestment (in shares)	614
Dividend reinvestment and stock purchase plan (in dollars per share)	$ 32.11
Grant of stock as payment of fees (in shares)	5
Grant of stock as payment of fees (in dollars per share)	$ 32.18
Equity shelf program (in shares)	228
Equity shelf program (in dollars per share)	$ 29.17
Common dividends (in dollars per share)	$ 1.25
Conversion of OP Units to Common stock (in shares)	89
Conversion of OP Units to Common stock (in dollars per share)	$ 32.91
Redemption of OP Units (in units)	90
Balance (in shares)	197,224	196,142
Balance (in units)	8,772	8,862
OHI Healthcare Properties Holdco, Inc.
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Balance (in shares)	1
Balance (in shares)	1	1

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net income	$ 177,269	$ 171,350
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	140,343	127,938
Impairment loss on real estate properties	17,773	41,451
Provision for uncollectible accounts	5,077	3,970
Refinancing costs and amortization of deferred financing costs	15,240	4,640
Accretion of direct financing leases	(6,164)	(5,915)
Stock-based compensation expense	7,478	6,443
Gain on assets sold - net	(6,798)	(14,792)
Amortization of acquired in-place leases - net	(6,202)	(7,910)
Effective yield receivable on mortgage notes	(1,191)	(619)
Change in operating assets and liabilities - net:
Contractual receivables	(33,293)	856
Straight-line rent receivables	(23,174)	(17,756)
Lease inducements	895	1,294
Other operating assets and liabilities	(21,667)	(24,055)
Net cash provided by operating activities	265,586	286,895
Cash flows from investing activities
Acquisition of real estate	(130,977)	(622,848)
Cash acquired	2,341
Investments in construction in progress	(46,108)	(26,960)
Investments in direct financing leases	(4,767)	(30)
Proceeds from direct financing leases	27,253
Placement of mortgage loans	(24,978)	(12,528)
Distributions from unconsolidated joint venture	9,741
Proceeds from sale of real estate investments	64,061	43,772
Capital improvements to real estate investments	(16,861)	(21,812)
Proceeds from other investments	35,997	25,923
Investments in other investments	(52,228)	(136,536)
Collection of mortgage principal	673	42,051
Net cash used in investing activities	(135,853)	(708,968)
Cash flows from financing activities
Proceeds from credit facility borrowings	817,000	879,000
Payments on credit facility borrowings	(852,000)	(639,000)
Receipts of other long-term borrowings	1,346,749	350,000
Payments of other long-term borrowings	(1,252,139)	(620)
Payments of financing related costs	(28,483)	(3,581)
Receipts from dividend reinvestment plan	19,721	93,333
Payments for exercised options and restricted stock	(2,120)	(2,380)
Net proceeds from issuance of common stock	6,634	487
Dividends paid	(246,722)	(217,068)
Redemption of Omega OP Units	(48)	(10)
Distributions to Omega OP Unit Holders	(11,143)	(10,351)
Net cash (used in) provided by financing activities	(202,551)	449,810
Effect of foreign currency translation on cash and cash equivalents	162	(202)
(Decrease) increase in cash and cash equivalents	(72,656)	27,535
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	21,031	32,959
Supplemental disclosures of cash flow information:
Interest paid during the period, net of amounts capitalized	97,610	74,010
Taxes paid during the period	2,032	748
Non cash investing activities
Non cash acquisition of real estate (See Note 2)	(9,430)
Non cash acquisition of business		(25,000)
Non cash surrender of mortgage		25,000
Non cash investment in other investments	(6,353)
Total	(15,783)
Non cash financing activities
Change in fair value of cash flow hedges	(108)	13,074
Remeasurement of debt denominated in a foreign currency	2,190
Non cash acquisition of real estate (See Note 2)	2,082	13,074
OHI Healthcare Properties Holdco, Inc.
Cash flows from operating activities
Net income	177,269	171,350
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	140,343	127,938
Impairment loss on real estate properties	17,773	41,451
Provision for uncollectible accounts	5,077	3,970
Refinancing costs and amortization of deferred financing costs	15,240	4,640
Accretion of direct financing leases	(6,164)	(5,915)
Stock-based compensation expense	7,478	6,443
Gain on assets sold - net	(6,798)	(14,792)
Amortization of acquired in-place leases - net	(6,202)	(7,910)
Effective yield receivable on mortgage notes	(1,191)	(619)
Change in operating assets and liabilities - net:
Contractual receivables	(33,293)	856
Straight-line rent receivables	(23,174)	(17,756)
Lease inducements	895	1,294
Other operating assets and liabilities	(21,667)	(24,055)
Net cash provided by operating activities	265,586	286,895
Cash flows from investing activities
Acquisition of real estate	(130,977)	(622,848)
Cash acquired	2,341
Investments in construction in progress	(46,108)	(26,960)
Investments in direct financing leases	(4,767)	(30)
Proceeds from direct financing leases	27,253
Placement of mortgage loans	(24,978)	(12,528)
Distributions from unconsolidated joint venture	9,741
Proceeds from sale of real estate investments	64,061	43,772
Capital improvements to real estate investments	(16,861)	(21,812)
Proceeds from other investments	35,997	25,923
Investments in other investments	(52,228)	(136,536)
Collection of mortgage principal	673	42,051
Net cash used in investing activities	(135,853)	(708,968)
Cash flows from financing activities
Proceeds from intercompany loans payable from Omega	2,163,749	1,229,000
Repayment of intercompany loans payable to Omega	(2,104,139)	(639,620)
Payment of financing related costs incurred by Omega	(28,483)	(3,581)
Dividends paid	(54,641)	(25,354)
Contributions from noncontrolling interests	24,235	91,440
Distributions to Omega OP Unit Holders	(203,272)	(202,075)
Net cash (used in) provided by financing activities	(202,551)	449,810
Effect of foreign currency translation on cash and cash equivalents	162	(202)
(Decrease) increase in cash and cash equivalents	(72,656)	27,535
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	21,031	32,959
Supplemental disclosures of cash flow information:
Interest paid during the period, net of amounts capitalized	97,610	74,010
Taxes paid during the period	2,032	748
Non cash investing activities
Non cash acquisition of real estate (See Note 2)	(9,430)
Non cash acquisition of business		(25,000)
Non cash surrender of mortgage		25,000
Non cash investment in other investments	(6,353)
Total	(15,783)
Non cash financing activities
Change in fair value of cash flow hedges	(108)	13,074
Remeasurement of debt denominated in a foreign currency	2,190
Non cash acquisition of real estate (See Note 2)	2,082	13,074
OHI Healthcare Properties Limited Partnership
Cash flows from operating activities
Net income	177,269	171,350
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	140,343	127,938
Impairment loss on real estate properties	17,773	41,451
Provision for uncollectible accounts	5,077	3,970
Refinancing costs and amortization of deferred financing costs	15,240	4,640
Accretion of direct financing leases	(6,164)	(5,915)
Stock-based compensation expense	7,478	6,443
Gain on assets sold - net	(6,798)	(14,792)
Amortization of acquired in-place leases - net	(6,202)	(7,910)
Effective yield receivable on mortgage notes	(1,191)	(619)
Change in operating assets and liabilities - net:
Contractual receivables	(33,293)	856
Straight-line rent receivables	(23,174)	(17,756)
Lease inducements	895	1,294
Other operating assets and liabilities	(21,667)	(24,055)
Net cash provided by operating activities	265,586	286,895
Cash flows from investing activities
Acquisition of real estate	(130,977)	(622,848)
Cash acquired	2,341
Investments in construction in progress	(46,108)	(26,960)
Investments in direct financing leases	(4,767)	(30)
Proceeds from direct financing leases	27,253
Placement of mortgage loans	(24,978)	(12,528)
Distributions from unconsolidated joint venture	9,741
Proceeds from sale of real estate investments	64,061	43,772
Capital improvements to real estate investments	(16,861)	(21,812)
Proceeds from other investments	35,997	25,923
Investments in other investments	(52,228)	(136,536)
Collection of mortgage principal	673	42,051
Net cash used in investing activities	(135,853)	(708,968)
Cash flows from financing activities
Proceeds from intercompany loans payable from Omega	2,163,749	1,229,000
Repayment of intercompany loans payable to Omega	(2,104,139)	(639,620)
Payment of financing related costs incurred by Omega	(28,483)	(3,581)
Equity contributions from general partners	24,235	91,440
Distributions to general partners	(246,722)	(217,068)
Distributions to limited partners	(11,143)	(10,351)
Redemption of Omega OP Units	(48)	(10)
Net cash (used in) provided by financing activities	(202,551)	449,810
Effect of foreign currency translation on cash and cash equivalents	162	(202)
(Decrease) increase in cash and cash equivalents	(72,656)	27,535
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	21,031	32,959
Supplemental disclosures of cash flow information:
Interest paid during the period, net of amounts capitalized	97,610	74,010
Taxes paid during the period	2,032	748
Non cash investing activities
Non cash acquisition of real estate (See Note 2)	(9,430)
Non cash acquisition of business		(25,000)
Non cash surrender of mortgage		25,000
Non cash investment in other investments	(6,353)
Total	(15,783)
Non cash financing activities
Change in fair value of cash flow hedges	(108)	13,074
Remeasurement of debt denominated in a foreign currency	2,190
Non cash acquisition of real estate (See Note 2)	$ 2,082	$ 13,074

BASIS OF PRESENTATION AND SIGNI

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview and Organization Omega Healthcare Investors, Inc. (“Omega”) was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. All of Omega's assets are owned directly or indirectly, and all of Omega's operations are conducted directly or indirectly, through its subsidiaries, OHI Healthcare Properties Holdco, Inc. (“OHI Holdco”), a direct wholly owned subsidiary of Omega, and OHI Healthcare Properties Limited Partnership (“Omega OP”). OHI Holdco was formed as a corporation and incorporated in the State of Delaware on October 22, 2014. Omega OP was formed as a limited partnership and organized in the State of Delaware on October 24, 2014. No substantive assets or activity occurred in either of these entities until the merger with Aviv REIT, Inc. on April 1, 2015. Unless stated otherwise or the context otherwise requires, the terms the “Company,” “we,” “our” and “us” means Omega, OHI Holdco and Omega OP, collectively. The Company has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”) and, to a lesser extent, assisted living facilities (“ALFs”), independent living facilities and rehabilitation and acute care facilities. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor. In April 2015, Aviv REIT, Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among Omega, Aviv, OHI Holdco, Omega OP, and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership. Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, all of Omega’s assets are held by Omega OP, through its equity interests in its subsidiaries. Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, Omega and OHI Holdco are the general partners of Omega OP, and have exclusive control over Omega OP’s day-to-day management. As of June 30, 2017, Omega and OHI Holdco together owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and investors owned approximately 4% of the Omega OP Units. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017. Our consolidated financial statements include the accounts of (i) Omega, (ii) OHI Holdco, (iii) Omega OP, and (iv) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Asset Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. Additionally, our evaluation of fair value may consider valuing the property as a nursing home as well as alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations. For the three and six months ended June 30, 2017 and 2016, we recognized impairment losses of $10.1 million, $17.8 million, $6.9 million and $41.5 million, respectively. For additional information see Note 2 – Properties and Investments. Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Income. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors. The noncontrolling interest for OHI Holdco represents the Omega OP Units held by the Parent and the outstanding Omega OP Units held by outside investors. Foreign Operations The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL. Derivative Instruments Cash flow hedges During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At June 30, 2017 and December 31, 2016, we had $1.4 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets. Net investment hedge We use the spot method to measure the effectiveness of our net investment hedge. Under this method, for each reporting period, the change in the carrying value of the hedging instrument due to remeasurement of the effective portion is reported in AOCL in our Consolidated Balance Sheets and the remaining change in the carrying value of the ineffective portion, if any, is recognized in earnings. We evaluate the effectiveness of our net investment hedge on a quarterly basis. We did not record any ineffectiveness for fiscal 2017. Accounts Receivable Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. At June 30, 2017, two of our top 10 operators were approximately 90 days past due on rent payments to the Company. On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and/or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. A summary of our net receivables by type is as follows: June 30, December 31, 2017 2016 (in thousands) Contractual receivables $ 40,484 $ 13,376 Effective yield interest receivables 10,940 9,749 Straight-line rent receivables 231,233 208,874 Lease inducements 7,498 8,393 Allowance (1,469 ) (357 ) Accounts receivable – net $ 288,686 $ 240,035 Related Party Transactions The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family. Accounting Pronouncement Adopted in 2017 In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Recent Accounting Pronouncements - Pending Adoption In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers Principal versus Agent Considerations (Reporting Revenue Gross versus Net), Identifying Performance Obligations and Licensing, Narrow-Scope Improvements and Practical Expedients. In February 2016, the FASB issued ASU 2016-02, Leases In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326

PROPERTIES AND INVESTMENTS

PROPERTIES AND INVESTMENTS	6 Months Ended
	Jun. 30, 2017
Real Estate [Abstract]
PROPERTIES AND INVESTMENTS	NOTE 2 – PROPERTIES AND INVESTMENTS Leased Property Our real estate properties, represented by 803 SNFs, 119 ALFs, 16 specialty facilities and one medical office building at June 30, 2017, are leased under provisions of single or master leases with initial terms typically ranging from five to 15 years, plus renewal options. Substantially all of our leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in one of three methods depending on specific provisions of each lease as follows: (i) a specific annual percentage increase over the prior year’s rent, generally between 2.0% and 3.0%; (ii) an increase based on the change in pre-determined formulas from year to year (e.g., increases in the Consumer Price Index (“CPI”)); or (iii) specific dollar increases over prior years. Under the terms of the leases, the lessee is responsible for all maintenance, repairs, taxes and insurance on the leased properties. A summary of our investment in leased real estate properties is as follows: June 30, December 31, 2017 2016 (in thousands) Buildings $ 6,055,423 $ 5,954,771 Land 796,561 759,295 Furniture, fixtures and equipment 458,427 454,760 Site improvements 204,993 206,206 Construction in progress 214,795 191,326 Total real estate investments 7,730,199 7,566,358 Less accumulated depreciation (1,366,376 ) (1,240,336 ) Real estate investments - net $ 6,363,823 $ 6,326,022 The following table summarizes the significant acquisitions that occurred during the first six months of 2017: Number of Country/ Total Land Building & Site Improvements Furniture Initial Period SNF ALF State (in millions) (2) Q1 - 1 VA $ 7.6 $ 0.5 $ 6.8 $ 0.3 7.50 Q2 1 - NC 8.6 0.7 7.3 0.6 9.50 Q2 - 18 UK 124.2 34.1 85.1 5.0 8.50 Total 1 19 $ 140.4 $ 35.3 $ 99.2 $ 5.9 (1) Omega recorded a non-cash deferred tax liability and acquisitions costs of approximately $8.2 million and $1.2 million, respectively, in connection with this acquisition. (2) The cash yield is based on the purchase price. During the second quarter of 2017, we acquired two parcels of land which are not reflected in the table above for approximately $5.5 million with the intent of building new facilities for an existing operator. Asset Sales, Impairments and Other During the first quarter of 2017, we sold 15 facilities for approximately $45.8 million in net proceeds recognizing a gain on sale of approximately $7.4 million. Eleven of the sold facilities were previously classified as held for sale. In addition, we recorded a provision for impairment of approximately $7.6 million on three facilities, one of which was reclassified to held for sale as of March 31, 2017. During the second quarter of 2017, we sold three facilities for approximately $18.3 million in net cash proceeds recognizing a loss on sale of approximately $0.6 million. Two of the sold facilities were previously classified as assets held for sale. In addition, we recorded a provision for impairment of approximately $10.1 million on six facilities. We reduced the net book value of the impaired facilities to their estimated fair values or, with respect to the facility reclassified to held for sale, to its estimated fair value less costs to sell. To estimate the fair value of the facilities, we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). Also see Note 7 – Assets Held For Sale for details. Our recorded impairments were primarily the result of a decision to exit certain non-strategic facilities and/or operators.

DIRECT FINANCING LEASES

DIRECT FINANCING LEASES	6 Months Ended
	Jun. 30, 2017
Leases, Capital [Abstract]
DIRECT FINANCING LEASES	NOTE 3 – DIRECT FINANCING LEASES The components of investments in direct financing leases consist of the following: June 30, December 31, 2017 2016 (in thousands) Minimum lease payments receivable $ 4,085,493 $ 4,287,069 Less unearned income (3,499,877 ) (3,685,131 ) Less allowance for loss on direct financing lease (3,309 ) — Investment in direct financing leases - net $ 582,307 $ 601,938 Properties subject to direct financing leases 53 58 The following minimum rents are due under our direct financing leases for the remainder of 2017 and the subsequent five years (in thousands): 2017 2018 2019 2020 2021 2022 $24,407 $50,019 $51,246 $52,493 $53,681 $55,008 New Ark Investment Inc. On November 27, 2013, we closed an aggregate $529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Company, Inc. (“Ark Holding”) by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities back to Ark Holding, now known as New Ark Investment Inc. (“New Ark”), pursuant to four 50-year master leases with rental payments yielding 10.6% per annum over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease. The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. In addition, commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the sum of the unamortized portion of the original aggregate $529 million investment plus the net present value of the remaining payments under the lease and closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time. The remaining 50 facilities under these master leases as of June 30, 2017 are located in 10 states, predominantly in the southeastern U.S. The facilities are separated by region and divided amongst four cross-defaulted master leases. The four regions include the Southeast (38 facilities), the Northwest (2 facilities), Texas (9 facilities) and Indiana (1 facility). Additionally, we own four facilities and lease them to New Ark under a master lease which expires in 2026. The four facility lease is being accounted for as an operating lease. In March 2017, we executed sale agreements with two unrelated third parties to sell seven facilities leased to New Ark located in the Northwest with a carrying value of approximately $36.4 million for approximately $34.0 million. During the first quarter of 2017, we recorded an allowance for loss of approximately $2.4 million. In the second quarter of 2017, we sold five of the Northwest facilities and received net cash proceeds of approximately $27.3 million and recorded an additional allowance for loss of approximately $0.9 million. For the three and six months ended June 30, 2017, we recognized approximately $0.5 million and $1.3 million, respectively, of direct financing lease income on a cash basis related to the Northwest facilities lease. The sale of the remaining two Northwest facilities is expected to close in the third quarter of 2017.

MORTGAGE NOTES RECEIVABLE

MORTGAGE NOTES RECEIVABLE	6 Months Ended
	Jun. 30, 2017
Mortgage Notes Receivable Investments [Abstract]
MORTGAGE NOTES RECEIVABLE	NOTE 4 – MORTGAGE NOTES RECEIVABLE As of June 30, 2017, mortgage notes receivable relate to 29 fixed rate mortgages on 52 long-term care facilities. The mortgage notes are secured by first mortgage liens on the borrowers' underlying real estate and personal property. The mortgage notes receivable relate to facilities located in ten states that are operated by seven independent healthcare operating companies. We monitor compliance with mortgages and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding mortgage notes. Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided against earned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of troubled operators lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage loans is recognized as received after taking into account the application of security deposits. The outstanding principal amounts of mortgage notes receivable, net of allowances, were as follows: June 30, December 31, 2017 2016 (in thousands) Mortgage note due 2024; interest at 9.98% $ 112,500 $ 112,500 Mortgage note due 2029; interest at 9.45% 411,467 412,140 Other mortgage notes outstanding (1) 143,489 118,637 Mortgage notes receivable, gross 667,456 643,277 Allowance for loss on mortgage notes receivable (4,747 ) (3,934 ) Total mortgages — net $ 662,709 $ 639,343 (1) Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 14.0% and maturity dates through 2029.

OTHER INVESTMENTS

OTHER INVESTMENTS	6 Months Ended
	Jun. 30, 2017
Receivables [Abstract]
OTHER INVESTMENTS	NOTE 5 – OTHER INVESTMENTS A summary of our other investments is as follows: June 30, December 31, 2017 2016 (in thousands) Other investment note due 2019; interest at 10.96% $ 49,583 $ 49,458 Other investment note due 2020; interest at 14.00% 47,899 47,913 Other investment note due 2022, interest at 9.00% 31,987 31,987 Other investment note due 2030; interest at 6.66% 50,000 44,595 Other investment notes outstanding (1) 104,314 87,691 Other investments, gross 283,783 261,644 Allowance for loss on other investments (4,798 ) (4,798 ) Total other investments $ 278,985 $ 256,846 (1) Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

INVESTMENT IN UNCONSOLIDATED JO

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE	6 Months Ended
	Jun. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN UNCONSOLIDATED JOINT VENTURE	NOTE 6 – INVESTMENT IN UNCONSOLIDATED JOINT VENTURE On November 1, 2016, we invested approximately $50.0 million for an approximate 15% ownership interest in a joint venture operating as Second Spring Healthcare Investments. The other approximate 85% interest is owned by affiliates of Lindsey Goldberg LLC. We account for the joint venture using the equity method. On November 1, 2016, the joint venture acquired 64 SNFs from Welltower Inc. for approximately $1.1 billion and leased them to a single operator. We receive asset management fees from the joint venture for services provided. For the three and six months ended June 30, 2017, we recognized $0.5 million and $1.0 million, respectively, of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statements of Income. The accounting policies for the unconsolidated joint venture are the same as those of the Company.

ASSETS HELD FOR SALE

ASSETS HELD FOR SALE	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
ASSETS HELD FOR SALE	NOTE 7 – ASSETS HELD FOR SALE The following is a summary of our assets held for sale: Properties Held For Sale Number of Net Book Value December 31, 2016 20 $ 52,868 Properties sold/other (1) (12 ) (30,023 ) Properties added (2) 1 400 March 31, 2017 9 $ 23,245 Properties sold/other (1) (2 ) (4,356 ) June 30, 2017 (3) 7 $ 18,889 (1) In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale. In the second quarter of 2017, we sold one ALF and one SNF for approximately $5.0 million in net proceeds, generating a gain on sale of approximately $0.6 million. (2) In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. (3) We plan to sell the facilities classified as held for sale at June 30, 2017 within the next twelve months.

INTANGIBLES

INTANGIBLES	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 8 – INTANGIBLES The following is a summary of our intangibles as of June 30, 2017 and December 31, 2016 June 30, December 31, 2017 2016 (in thousands) Assets: Goodwill $ 644,184 $ 643,474 Above market leases $ 22,426 $ 22,476 In-place leases 167 167 Accumulated amortization (16,477 ) (15,864 ) Net intangible assets $ 6,116 $ 6,779 Liabilities: Below market leases $ 164,735 $ 165,028 Accumulated amortization (77,534 ) (70,738 ) Net intangible liabilities $ 87,201 $ 94,290 Above market leases and in-place leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Income as an adjustment to rental income. For the three months ended June 30, 2017 and 2016, our net amortization related to intangibles was $3.1 million and $3.6 million, respectively. For the six months ended June 30, 2017 and 2016, our net amortization related to intangibles was $6.2 million and $7.9 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2017 and the subsequent four years is as follows: remainder of 2017 – $5.8 million; 2018 – $10.5 million; 2019 – $9.5 million; 2020 – $9.3 million and 2021 – $8.7 million. As of June 30, 2017 the weighted average remaining amortization period of above market leases (inclusive of in-place leases) and below market leases is approximately eight years and nine years, respectively. The following is a reconciliation of our goodwill as of June 30, 2017: (in thousands) Balance as of December 31, 2016 $ 643,474 Add: foreign currency translation 710 Balance as of June 30, 2017 $ 644,184

CONCENTRATION OF RISK

CONCENTRATION OF RISK	6 Months Ended
	Jun. 30, 2017
Risks and Uncertainties [Abstract]
CONCENTRATION OF RISK	NOTE 9 – CONCENTRATION OF RISK As of June 30, 2017, our portfolio of real estate investments consisted of 999 healthcare facilities, located in 42 states and the U.K. and operated by 77 third party operators. Our investment in these facilities, net of impairments and reserve for uncollectible loans, totaled approximately $9.0 billion at June 30, 2017, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio is made up of 803 SNFs, 119 ALFs, 16 specialty facilities, one medical office building, fixed rate mortgages on 47 SNFs and four ALFs, and nine facilities that are closed/held-for-sale. At June 30, 2017, we also held other investments of approximately $279.0 million, consisting primarily of secured loans to third-party operators of our facilities and a $39.0 million investment in an unconsolidated joint venture. At June 30, 2017, we had investments with one operator/or manager that exceeded 10% of our total investments: Ciena Healthcare (10%). No operator generated more than 10% of our total revenues from operations for the three and six months ended June 30, 2017. At June 30, 2017, the three states in which we had our highest concentration of investments were Ohio (9%), Texas (9%) and Florida (9%).

STOCKHOLDERS'_OWNERS' EQUITY

STOCKHOLDERS'/OWNERS' EQUITY	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDERS'/OWNERS' EQUITY	NOTE 10 – STOCKHOLDERS’/OWNERS' EQUITY On July 13, 2017, the Board of Directors declared a common stock dividend of $0.64 per share, increasing the quarterly common dividend rate by $0.01 per share over the prior quarter, to be paid on August 15, 2017 to common stockholders of record as of the close of business on August 1, 2017. On April 13, 2017, the Board of Directors declared a common stock dividend of $0.63 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter. The common dividends were paid May 15, 2017 to common stockholders of record as of the close of business on May 1, 2017. On January 12, 2017, the Board of Directors declared a common stock dividend of $0.62 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter. The common dividends were paid February 15, 2017 to common stockholders of record as of the close of business on January 31, 2017. On the same dates listed above, Omega OP Unit holders received the same distributions per unit as those paid to the common stockholders of Omega. $500 Million Equity Shelf Program For the three months ended June 30, 2017, no shares were issued under our $500 million Equity Shelf Program. For the six months ended June 30, 2017, we issued 0.2 million shares of common stock at an average price of $29.17 per share, net of issuance costs, generating net proceeds of $6.6 million under our $500 million Equity Shelf Program. Dividend Reinvestment and Common Stock Purchase Plan For the three months ended June 30, 2017, approximately 0.4 million shares of our common stock at an average price of $33.02 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $12.4 million. For the six months ended June 30, 2017, approximately 0.6 million shares of our common stock at an average price of $32.11 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $19.7 million. Accumulated Other Comprehensive Loss The following is a summary of our accumulated other comprehensive loss, net of tax where applicable: Omega As of and For the Three As of and For the Six 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (50,614 ) $ (13,143 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,195 (21,836 ) 14,468 (26,544 ) Realized gain (loss) 79 - 140 (22 ) Ending balance (40,340 ) (34,979 ) (40,340 ) (34,979 ) Derivative Instruments: Cash flow hedges: Beginning balance (166 ) (9,594 ) (1,420 ) (718 ) Unrealized loss (1,840 ) (4,198 ) (1,350 ) (13,074 ) Realized gain 626 - 1,390 - Ending balance (1,380 ) (13,792 ) (1,380 ) (13,792 ) Net investment hedge: Beginning balance - - - - Unrealized loss (2,193 ) - (2,193 ) - Ending balance (2,193 ) - (2,193 ) - Total accumulated other comprehensive loss (43,913 ) (48,771 ) (43,913 ) (48,771 ) Add: portion included in noncontrolling interest 2,010 2,308 2,010 2,308 Total accumulated other comprehensive loss $ (41,903 ) $ (46,463 ) $ (41,903 ) $ (46,463 ) OHI Holdco As of and For the Three As of and For the Six 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (50,614 ) $ (13,143 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,195 (21,836 ) 14,468 (26,544 ) Realized gain (loss) 79 - 140 (22 ) Ending balance (40,340 ) (34,979 ) (40,340 ) (34,979 ) Derivative Instruments: Cash flow hedges: Beginning balance (166 ) (9,594 ) (1,420 ) (718 ) Unrealized loss (1,840 ) (4,198 ) (1,350 ) (13,074 ) Realized gain 626 - 1,390 - Ending balance (1,380 ) (13,792 ) (1,380 ) (13,792 ) Net investment hedge: Beginning balance - - - - Unrealized loss (2,193 ) - (2,193 ) - Ending balance (2,193 ) - (2,193 ) - Total accumulated other comprehensive loss (43,913 ) (48,771 ) (43,913 ) (48,771 ) Add: portion included in noncontrolling interest 34,116 37,965 34,116 37,965 Total accumulated other comprehensive loss $ (9,797 ) $ (10,806 ) $ (9,797 ) $ (10,806 ) Omega OP As of and For the Three As of and For the Six 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (50,614 ) $ (13,143 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,195 (21,836 ) 14,468 (26,544 ) Realized gain (loss) 79 - 140 (22 ) Ending balance (40,340 ) (34,979 ) (40,340 ) (34,979 ) Derivative Instruments: Cash flow hedges: Beginning balance (166 ) (9,594 ) (1,420 ) (718 ) Unrealized loss (1,840 ) (4,198 ) (1,350 ) (13,074 ) Realized gain 626 - 1,390 - Ending balance (1,380 ) (13,792 ) (1,380 ) (13,792 ) Net investment hedge: Beginning balance - - - - Unrealized loss (2,193 ) - (2,193 ) - Ending balance (2,193 ) - (2,193 ) - Total accumulated other comprehensive loss $ (43,913 ) $ (48,771 ) $ (43,913 ) $ (48,771 )

TAXES

TAXES	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
TAXES	NOTE 11 – TAXES OHI Holdco is a wholly owned subsidiary of Omega and is a qualified REIT subsidiary for United States federal income tax purposes, and Omega OP is a pass through entity for United States federal income tax purposes. Since our inception, we have elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code (“Code”). A REIT is generally not subject to federal income tax on that portion of its REIT taxable income which is distributed to its stockholders, provided that at least 90% of such taxable income is distributed each tax year and certain other requirements are met, including asset and income tests. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. If the Company fails to qualify as a REIT in any taxable year, the Company will be subject to federal income taxes on its taxable income at regular corporate rates and dividends paid to our stockholders will not be deductible by us in computing taxable income. Further, we will not be permitted to qualify for treatment as a REIT for federal income tax purposes for four years following the year in which qualification is denied, unless the Internal Revenue Service grants us relief under certain statutory provisions. Failing to qualify as a REIT could materially and adversely affect the Company’s net income; however, we believe we are organized and operate in such a manner as to qualify for treatment as a REIT. We test our compliance within the REIT taxation rules to ensure that we are in compliance with the REIT rules on a quarterly and annual basis. We review our distributions and projected distributions each year to ensure we have met and will continue to meet the annual REIT distribution requirements. In 2017, we expect to distribute dividends in excess of our taxable income. As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. Also, as a result of our UPREIT Conversion, we created five wholly owned subsidiary REITs and added a sixth wholly owned subsidiary REIT as of January 1, 2016, all of which are subject to all of the REIT qualification rules set forth in the Code. We merged five of the wholly owned subsidiary REITs into a single wholly owned subsidiary REIT in December 2015, and then merged the sixth wholly owned subsidiary REIT into our other wholly owned subsidiary REIT in December 2016, which wholly owned subsidiary REIT remains subject to all of the REIT qualification rules set forth in the Code. Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our active subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of June 30, 2017, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately $0.8 million. The loss carry-forward is fully reserved as of June 30, 2017, with a valuation allowance due to uncertainties regarding realization. During the second quarter of 2017, we recorded approximately $0.5 million of state and local income tax provision and approximately $0.1 million of tax provision for foreign income taxes. For the six months ended June 30, 2017, we recorded approximately $1.5 million of state and local income tax provision and approximately $0.2 million of tax provision for foreign income taxes. The expenses were included in provision for income taxes on our Consolidated Statements of Income.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK-BASED COMPENSATION	NOTE 12 – STOCK-BASED COMPENSATION The following is a summary of our stock-based compensation expense for the three and six months ended June 30, 2017 and 2016, respectively: Three Months Ended Six Months Ended 2017 2016 2017 2016 (in thousands) Stock-based compensation expense $ 3,734 $ 3,665 $ 7,478 $ 6,443 Restricted Stock and Restricted Stock Units Restricted stock and restricted stock units (“RSUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. Restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. We expense the cost of these awards ratably over their vesting period. We awarded 140,416 RSUs to employees on January 1, 2017. Performance Restricted Stock Units and LTIP Units Performance restricted stock units (“PRSUs”) and long term incentive plan units (“LTIP Units”) are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. The PRSUs and the LTIP Units have varying degrees of performance requirements to be earned and vested, and each PRSU and LTIP Units award represents the right to a variable number of shares of common stock or partnership units. Each LTIP Unit once earned and vested is convertible into one Omega OP Unit in Omega OP, subject to certain conditions. The earning requirements are based on either the (i) total shareholder return (“TSR”) of Omega or (ii) Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR (both “Relative TSR”). Vesting in general requires that the employee remain employed by us until the date specified in the applicable PRSU or LTIP agreement, which may be later than the date that the TSR or Relative TSR requirements are satisfied. We expense the cost of these awards ratably over their service period. Prior to vesting and the distribution of shares, ownership of the PRSUs cannot be transferred. Dividend equivalents on the PRSUs accumulate and with respect to PRSUs granted before 2015 are paid when the PRSUs vest and with respect to PRSUs granted in 2015 or later are paid once the PRSUs are earned. While each LTIP Unit is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock) on the LTIP Units accumulate, and if the LTIP Units are earned, the accumulated distributions are paid. The number of shares or units earned under the TSR PRSUs or LTIP Units depends generally on the level of achievement of Omega’s TSR over the indicated performance period. We awarded 399,726 LTIP Units to employees on January 1, 2017. The number of shares earned under the Relative TSR PRSUs depends generally on the level of achievement of Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR over the performance period indicated. We awarded 285,338 Relative TSR PRSUs to employees on January 1, 2017. The following table summarizes our total unrecognized compensation cost as of June 30, 2017 associated with restricted stock, restricted stock units, PRSU awards, and LTIP Unit awards to employees: Grant Year Shares/ Units Grant Date Average Fair Value Per Unit/ Share Total Compensation Cost (in millions) (1) Weighted Average Period of Expense Recognition (in months) Unrecognized Compensation Cost (in millions) Performance Period Vesting Dates RSUs 3/31/15 RSU 2015 109,985 $ 40.57 $ 4.5 33 $ 0.8 N/A 12/31/2017 4/1/15 RSU 2015 40,464 40.74 1.6 33 0.3 N/A 12/31/2017 Assumed Aviv RSU 2015 7,799 35.08 0.3 33 0.1 N/A 11/1/2017 3/17/16 RSU 2016 130,006 34.78 4.6 33 2.4 N/A 12/31/2018 1/1/2017 RSU 2017 140,416 31.26 4.3 36 3.6 N/A 12/31/2019 Restricted Stock Units Total 428,670 $ 35.68 $ 15.3 $ 7.2 TSR PRSUs and LTIP Units 2016 TSR 2014 135,634 $ 8.67 $ 1.2 48 $ 0.2 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 LTIP Units 2015 137,249 14.66 2.0 45 0.8 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 LTIP Units 2015 54,151 14.80 0.8 45 0.3 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 LTIP Units 2016 372,069 13.21 4.9 45 3.2 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 LTIP Units 2017 399,726 12.61 5.0 48 4.4 1/1/2017-12/31/2019 Quarterly in 2020 TSR PRSUs & LTIP Total 1,098,829 $ 12.69 $ 13.9 $ 8.9 Relative TSR PRSUs 2016 Relative TSR 2014 135,634 $ 14.24 $ 1.9 48 $ 0.2 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 Relative TSR 2015 137,249 22.50 3.1 45 1.2 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 Relative TSR 2015 54,151 22.91 1.2 45 0.5 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 Relative TSR 2016 307,480 16.45 5.1 45 3.4 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 Relative TSR 2017 285,338 18.04 5.1 48 4.5 1/1/2017-12/31/2019 Quarterly in 2020 Relative TSR PRSUs Total 919,852 $ 17.78 $ 16.4 $ 9.8 Grand Total 2,447,351 $ 18.63 $ 45.6 $ 25.9 (1) Total compensation costs are net of shares cancelled. Director Restricted Stock Grants As of June 30, 2017, we had 90,421 shares of restricted stock outstanding to directors. The outstanding restricted stock granted to directors prior to 2017 is scheduled to vest ratably over three years from the date of grant. Beginning with the 2017 grants, director restricted stock grants fully vest at the annual meeting following the grant date. As of June 30, 2017, the unrecognized compensation cost associated with outstanding director restricted stock grants is approximately $2.2 million.

BORROWING ACTIVITIES AND ARRANG

BORROWING ACTIVITIES AND ARRANGEMENTS	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
BORROWING ACTIVITIES AND ARRANGEMENTS	NOTE 13 – BORROWING ACTIVITIES AND ARRANGEMENTS Secured and Unsecured Borrowings The following is a summary of our borrowings: Annual Interest June 30, June 30, December 31, Maturity 2017 2017 2016 (in thousands) Secured borrowings: HUD mortgages assumed December 2011 (1) 2044 3.06% $ 54,316 $ 54,954 Deferred financing costs – net (579 ) (589 ) Total secured borrowings – net (2) 53,737 54,365 Unsecured borrowings: Revolving line of credit 2021 2.47% 155,000 190,000 Tranche A-1 term loan - - — 200,000 Tranche A-2 term loan - - — 200,000 Tranche A-3 term loan - - — 350,000 U.S. term loan 2022 2.67% 425,000 — Sterling term loan 2022 1.70% 130,250 — Omega OP term loan (2) 2022 2.67% 100,000 100,000 2015 term loan 2022 3.80% 250,000 250,000 Discounts and deferred financing costs – net (3) (5,958 ) (5,657 ) Total term loans – net 899,292 1,094,343 2023 notes 2023 4.375% 700,000 700,000 2024 notes 2024 5.875% — 400,000 2024 notes 2024 4.95% 400,000 400,000 2025 notes 2025 4.50% 400,000 250,000 2026 notes 2026 5.25% 600,000 600,000 2027 notes 2027 4.50% 700,000 700,000 2028 notes 2028 4.75% 550,000 — Other 2018 - 1,500 3,000 Subordinated debt 2021 9.00% 20,000 20,000 Discount - net (22,345 ) (17,151 ) Deferred financing costs – net (27,297 ) (27,703 ) Total unsecured borrowings – net 3,321,858 3,028,146 Total secured and unsecured borrowings – net $ 4,429,887 $ 4,366,854 (1) Reflects the weighted average annual contractual interest rate on the mortgages at June 30, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $63.9 million as of June 30, 2017. (2) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP. (3) This amount includes $0.6 million of net deferred financing costs related to the Omega OP term loan as of June 30, 2017. Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of June 30, 2017 and December 31, 2016, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. OHI Holdco and Omega OP, the guarantors of Parent’s outstanding senior notes, do not directly own any substantive assets other than OHI Holdco’s interest in Omega OP and Omega OP’s interest in non-guarantor subsidiaries. New and Amended Unsecured Credit Facility – 2017 2017 Omega Credit Facilities On May 25, 2017, Omega entered into a credit agreement (the “2017 Omega Credit Agreement”) providing us with a new $1.8 billion senior unsecured revolving and term loan credit facility, consisting of a $1.25 billion senior unsecured multicurrency revolving credit facility (the “Revolving Credit Facility”), a $425 million senior unsecured U.S. Dollar term loan facility (the “U.S. Term Loan Facility”), and a £100 million senior unsecured British Pound Sterling term loan facility (the “Sterling Term Loan Facility” and, together with the Revolving Credit Facility and the U.S. Term Loan Facility, collectively, the “2017 Omega Credit Facilities”). The 2017 Omega Credit Agreement contains an accordion feature permitting us, subject to compliance with customary conditions, to increase the maximum aggregate commitments under the 2017 Omega Credit Facilities to $2.5 billion. The 2017 Omega Credit Facilities replace the previous $1.25 billion senior unsecured 2014 revolving credit facility, the previous $200 million Tranche A-1 senior unsecured term loan facility, and the previous $350 million Tranche A-3 senior unsecured incremental term loan facility established under our 2014 credit agreement, which has been terminated (the “2014 Omega Credit Agreement”). We had previously repaid and terminated the $200 million Tranche A-2 senior unsecured term loan facility established under the 2014 Omega Credit Agreement, with proceeds from our $550 million and $150 million unsecured senior notes issued in April 2017. The Revolving Credit Facility bears interest at LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Revolving Credit Facility matures on May 25, 2021, subject to an option by us to extend such maturity date for two, six month periods. The 2017 Omega Credit Agreement provides for the Revolving Credit Facility to be drawn in Euros, British Pounds Sterling, Canadian Dollars (collectively, “Alternative Currencies”) or U.S. Dollars, with a $900 million tranche available in U.S. Dollars and a $350 million tranche available in U.S. Dollars or Alternative Currencies. For purposes of the 2017 Omega Credit Facilities, references to LIBOR include the Canadian dealer offered rates for amounts offered in Canadian Dollars and any other Alternative Currency rate approved in accordance with the terms of the 2017 Omega Credit Agreement for amounts offered in any other non-London interbank offered rate quoted currency, as applicable. The U.S. Term Loan Facility and the Sterling Term Loan Facility bear interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The U.S. Term Loan Facility and the Sterling Term Loan Facility each mature on May 25, 2022. For the three month period ending June 30, 2017, we recorded a one-time, non-cash charge of approximately $5.5 million relating to the write-off of deferred financing costs associated with the termination of the 2014 Omega Credit Facilities. Amended 2015 Term Loan Facility On May 25, 2017, Omega entered into an amended and restated credit agreement (the “Amended 2015 Credit Agreement”), which amended and restated our previous $250 million senior unsecured term loan facility (the “Amended 2015 Term Loan Facility”). The Amended 2015 Term Loan Facility bears interest at LIBOR plus an applicable percentage (with a range of 140 to 235 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Amended 2015 Term Loan Facility continues to mature on December 16, 2022. The Amended 2015 Credit Agreement permits us, subject to compliance with customary conditions, to add one or more incremental tranches to the Amended 2015 Term Loan Facility in an aggregate principal amount not exceeding $150 million. Omega’s obligations under the 2017 Omega Credit Facilities and the Amended 2015 Term Loan Facility are jointly and severally guaranteed by Omega OP, OHI Holdco, and any domestic subsidiary of Omega that provides a guaranty of any unsecured indebtedness of Omega for borrowed money evidenced by bonds, debentures, notes or other similar instruments in an amount of at least $50 million individually or in the aggregate. 2017 Omega OP Term Loan Facility On May 25, 2017, Omega OP Omega OP’s obligations in connection with the 2017 Omega OP $550 Million 4.75% Senior Notes and $150 Million 4.5% Senior Notes On April 4, 2017, Omega issued (i) $550 million aggregate principal amount of our 4.75% Senior Notes due 2028 (the “2028 Notes”) and (ii) an additional $150 million aggregate principal amount of our existing 4.50% Senior Notes due 2025 (the “2025 Notes”, and together with the 2028 Notes collectively, the “Notes”). The 2028 Notes mature on January 15, 2028 and the 2025 Notes mature on January 15, 2025. The 2028 Notes were sold at an issue price of 98.978% of their face value before the underwriters’ discount and the 2025 Notes were sold at an issue price of 99.540% of their face value before the underwriters’ discount. Our net proceeds from the Notes offering, after deducting underwriting discounts and expenses, were approximately $690.7 million. The net proceeds from the Notes offering were used to (i) redeem all of our outstanding $400 million aggregate principal amount of 5.875% Senior Notes due 2024 (the “5.875% Notes”) on April 28, 2017, (ii) prepay the $200 million Tranche A-2 Term Loan Facility on April 5, 2017 that otherwise would have become due on June 27, 2017, and (iii) repay outstanding borrowings under our revolving credit facility. $400 Million 5.875% Senior Notes Redemption On April 28, 2017, Omega redeemed all of our outstanding 5.875% Notes. As a result of the redemption, during the second quarter of 2017, we recorded approximately $16.5 million in redemption related costs and write-offs, including $11.8 million for the call premium and $4.7 million in net write-offs associated with unamortized deferred financing costs.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS	NOTE 14 – FINANCIAL INSTRUMENTS The carrying amount of cash and cash equivalents, restricted cash and accounts receivable reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (i.e., less than 90 days) (Level 1). At June 30, 2017 and December 31, 2016, the carrying amounts and fair values of our other financial instruments were as follows: June 30, 2017 December 31, 2016 Carrying Amount Fair Value Carrying Amount Fair Value (in thousands) Assets: Investments in direct financing leases – net $ 582,307 $ 578,998 $ 601,938 $ 598,665 Mortgage notes receivable – net 662,709 676,396 639,343 644,961 Other investments – net 278,985 271,306 256,846 253,385 Total $ 1,524,001 $ 1,526,700 $ 1,498,127 $ 1,497,011 Liabilities: Revolving line of credit $ 155,000 $ 155,000 $ 190,000 $ 190,000 Tranche A-1 term loan — — 198,830 200,000 Tranche A-2 term loan — — 200,000 200,000 Tranche A-3 term loan — — 347,449 350,000 U.S. term loan 422,280 425,000 — — Sterling term loan 129,413 130,250 — — Omega OP term loan (1) 99,373 100,000 100,000 100,000 2015 term loan 248,226 250,000 248,064 250,000 4.375% notes due 2023 – net 692,890 723,805 692,305 693,505 5.875% notes due 2024 – net — — 395,065 432,938 4.95% notes due 2024 – net 393,175 421,504 392,669 406,361 4.50% notes due 2025 – net 394,368 361,983 245,949 249,075 5.25% notes due 2026 – net 593,969 641,199 593,616 611,461 4.50% notes due 2027 – net 685,784 703,514 685,052 681,978 4.75% notes due 2028 – net 539,741 557,520 — — HUD debt – net (1) 53,737 52,535 54,365 52,510 Subordinated debt – net 20,431 24,045 20,490 23,944 Other 1,500 1,500 3,000 3,000 Total $ 4,429,887 $ 4,547,855 $ 4,366,854 $ 4,444,772 (1) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP. Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2016, as amended). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. The following methods and assumptions were used in estimating fair value disclosures for financial instruments. · Direct financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3). · Mortgage notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). · Other investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). · Revolving line of credit and term loans: The fair value of our borrowings under variable rate agreements are estimated using a present value technique based on expected cash flows discounted using the current market rates (Level 3). · Senior notes and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using a present value technique based on inputs from trading activity provided by a third party (Level 2). · HUD debt: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2).

LITIGATION

LITIGATION	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
LITIGATION	NOTE 15 – LITIGATION We are subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations.

EARNINGS PER SHARE_UNIT

EARNINGS PER SHARE/UNIT	6 Months Ended
	Jun. 30, 2017
Net Income Available To Common Per Share
EARNINGS PER SHARE/UNIT	NOTE 16 – EARNINGS PER SHARE/UNIT The computation of basic earnings per share/unit (“EPS” or “EPU”) is computed by dividing net income available to common stockholders/Omega OP Unit holders by the weighted-average number of shares of common stock/Omega OP Units outstanding during the relevant period. Diluted EPS/EPU is computed using the treasury stock method, which is net income divided by the total weighted-average number of common outstanding shares/Omega OP Units plus the effect of dilutive common equivalent shares/units during the respective period. Dilutive common shares/Omega OP Units reflect the assumed issuance of additional common shares pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock units and the assumed issuance of additional shares related to Omega OP Units held by outside investors. Dilutive Omega OP Units reflect the assumed issuance of additional Omega OP Units pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock. No per share information was provided for OHI Holdco because the sole stockholder is Omega. OHI Holdco is a wholly owned subsidiary of Omega and has 1,000 shares of $0.01 par value per share common stock outstanding. The following tables set forth the computation of basic and diluted earnings per share/unit: Omega Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net income $ 68,157 $ 113,154 $ 177,269 $ 171,350 Less: net income attributable to noncontrolling interests (2,900 ) (5,102 ) (7,572 ) (7,743 ) Net income available to common stockholders $ 65,257 $ 108,052 $ 169,697 $ 163,607 Denominator: Denominator for basic earnings per share 197,433 188,981 197,223 188,604 Effect of dilutive securities: Common stock equivalents 467 1,254 407 1,215 Noncontrolling interest – Omega OP Units 8,772 8,922 8,793 8,935 Denominator for diluted earnings per share 206,672 199,157 206,423 198,754 Earnings per share – basic: Net income available to common stockholders $ 0.33 $ 0.57 $ 0.86 $ 0.87 Earnings per share – diluted: Net income $ 0.33 $ 0.57 $ 0.86 $ 0.86 Omega OP Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net income $ 68,157 $ 113,154 $ 177,269 $ 171,350 Denominator: Denominator for basic earnings per unit 206,205 197,903 206,016 197,539 Effect of dilutive securities: Omega OP Unit equivalents 467 1,254 407 1,215 Denominator for diluted earnings per unit 206,672 199,157 206,423 198,754 Earnings per unit – basic: Net income available to Omega OP Unit holders $ 0.33 $ 0.57 $ 0.86 $ 0.87 Earnings per unit – diluted: Net income $ 0.33 $ 0.57 $ 0.86 $ 0.86

BASIS OF PRESENTATION AND SIG25

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017. Our consolidated financial statements include the accounts of (i) Omega, (ii) OHI Holdco, (iii) Omega OP, and (iv) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.
Asset Impairment	Asset Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. Additionally, our evaluation of fair value may consider valuing the property as a nursing home as well as alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations. For the three and six months ended June 30, 2017 and 2016, we recognized impairment losses of $10.1 million, $17.8 million, $6.9 million and $41.5 million, respectively. For additional information see Note 2 – Properties and Investments.
Goodwill Impairment	Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Income. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors. The noncontrolling interest for OHI Holdco represents the Omega OP Units held by the Parent and the outstanding Omega OP Units held by outside investors.
Foreign Operations	Foreign Operations The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL.
Derivative Instruments	Derivative Instruments Cash flow hedges During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At June 30, 2017 and December 31, 2016, we had $1.4 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets. Net investment hedge We use the spot method to measure the effectiveness of our net investment hedge. Under this method, for each reporting period, the change in the carrying value of the hedging instrument due to remeasurement of the effective portion is reported in AOCL in our Consolidated Balance Sheets and the remaining change in the carrying value of the ineffective portion, if any, is recognized in earnings. We evaluate the effectiveness of our net investment hedge on a quarterly basis. We did not record any ineffectiveness for fiscal 2017.
Accounts Receivable	Accounts Receivable Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. At June 30, 2017, two of our top 10 operators were approximately 90 days past due on rent payments to the Company. On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and/or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. A summary of our net receivables by type is as follows: June 30, December 31, 2017 2016 (in thousands) Contractual receivables $ 40,484 $ 13,376 Effective yield interest receivables 10,940 9,749 Straight-line rent receivables 231,233 208,874 Lease inducements 7,498 8,393 Allowance (1,469 ) (357 ) Accounts receivable – net $ 288,686 $ 240,035
Related Party Transactions	Related Party Transactions The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family.
Accounting Pronouncement Adopted in 2017	Accounting Pronouncement Adopted in 2017 In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718)
Recent Accounting Pronouncements - Pending Adoption	Recent Accounting Pronouncements - Pending Adoption In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers Principal versus Agent Considerations (Reporting Revenue Gross versus Net), Identifying Performance Obligations and Licensing, Narrow-Scope Improvements and Practical Expedients. In February 2016, the FASB issued ASU 2016-02, Leases In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326

BASIS OF PRESENTATION AND SIG26

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of summary of net receivables	June 30, December 31, 2017 2016 (in thousands) Contractual receivables $ 40,484 $ 13,376 Effective yield interest receivables 10,940 9,749 Straight-line rent receivables 231,233 208,874 Lease inducements 7,498 8,393 Allowance (1,469 ) (357 ) Accounts receivable – net $ 288,686 $ 240,035

PROPERTIES AND INVESTMENTS (Tab

PROPERTIES AND INVESTMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Real Estate [Abstract]
Schedule of investment in leased real estate properties	June 30, December 31, 2017 2016 (in thousands) Buildings $ 6,055,423 $ 5,954,771 Land 796,561 759,295 Furniture, fixtures and equipment 458,427 454,760 Site improvements 204,993 206,206 Construction in progress 214,795 191,326 Total real estate investments 7,730,199 7,566,358 Less accumulated depreciation (1,366,376 ) (1,240,336 ) Real estate investments - net $ 6,363,823 $ 6,326,022
Schedule of significant acquisitions	Number of Country/ Total Land Building & Site Improvements Furniture Initial Period SNF ALF State (in millions) (2) Q1 - 1 VA $ 7.6 $ 0.5 $ 6.8 $ 0.3 7.50 Q2 1 - NC 8.6 0.7 7.3 0.6 9.50 Q2 - 18 UK 124.2 34.1 85.1 5.0 8.50 Total 1 19 $ 140.4 $ 35.3 $ 99.2 $ 5.9 (1) Omega recorded a non-cash deferred tax liability and acquisitions costs of approximately $8.2 million and $1.2 million, respectively, in connection with this acquisition. (2) The cash yield is based on the purchase price.

DIRECT FINANCING LEASES (Tables

DIRECT FINANCING LEASES (Tables)	6 Months Ended
	Jun. 30, 2017
Leases, Capital [Abstract]
Schedule of components of investment in direct financing leases	June 30, December 31, 2017 2016 (in thousands) Minimum lease payments receivable $ 4,085,493 $ 4,287,069 Less unearned income (3,499,877 ) (3,685,131 ) Less allowance for loss on direct financing lease (3,309 ) — Investment in direct financing leases - net $ 582,307 $ 601,938 Properties subject to direct financing leases 53 58
Schedule of rents due under direct financing leases for remainder of 2017 and subsequent five years	2017 2018 2019 2020 2021 2022 $24,407 $50,019 $51,246 $52,493 $53,681 $55,008

MORTGAGE NOTES RECEIVABLE (Tabl

MORTGAGE NOTES RECEIVABLE (Tables)	6 Months Ended
	Jun. 30, 2017
Mortgage Notes Receivable Investments [Abstract]
Schedule of outstanding principal amounts of mortgage notes receivable, net of allowances	June 30, December 31, 2017 2016 (in thousands) Mortgage note due 2024; interest at 9.98% $ 112,500 $ 112,500 Mortgage note due 2029; interest at 9.45% 411,467 412,140 Other mortgage notes outstanding (1) 143,489 118,637 Mortgage notes receivable, gross 667,456 643,277 Allowance for loss on mortgage notes receivable (4,747 ) (3,934 ) Total mortgages — net $ 662,709 $ 639,343 (1) Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 14.0% and maturity dates through 2029.

OTHER INVESTMENTS (Tables)

OTHER INVESTMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Receivables [Abstract]
Schedule of other investments	June 30, December 31, 2017 2016 (in thousands) Other investment note due 2019; interest at 10.96% $ 49,583 $ 49,458 Other investment note due 2020; interest at 14.00% 47,899 47,913 Other investment note due 2022, interest at 9.00% 31,987 31,987 Other investment note due 2030; interest at 6.66% 50,000 44,595 Other investment notes outstanding (1) 104,314 87,691 Other investments, gross 283,783 261,644 Allowance for loss on other investments (4,798 ) (4,798 ) Total other investments $ 278,985 $ 256,846 (1) Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

ASSETS HELD FOR SALE (Tables)

ASSETS HELD FOR SALE (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
Schedule of properties held-for-sale	Properties Held For Sale Number of Net Book Value December 31, 2016 20 $ 52,868 Properties sold/other (1) (12 ) (30,023 ) Properties added (2) 1 400 March 31, 2017 9 $ 23,245 Properties sold/other (1) (2 ) (4,356 ) June 30, 2017 (3) 7 $ 18,889 (1) In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale. In the second quarter of 2017, we sold one ALF and one SNF for approximately $5.0 million in net proceeds, generating a gain on sale of approximately $0.6 million. (2) In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. (3) We plan to sell the facilities classified as held for sale at June 30, 2017 within the next twelve months.

INTANGIBLES (Tables)

INTANGIBLES (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangibles	June 30, December 31, 2017 2016 (in thousands) Assets: Goodwill $ 644,184 $ 643,474 Above market leases $ 22,426 $ 22,476 In-place leases 167 167 Accumulated amortization (16,477 ) (15,864 ) Net intangible assets $ 6,116 $ 6,779 Liabilities: Below market leases $ 164,735 $ 165,028 Accumulated amortization (77,534 ) (70,738 ) Net intangible liabilities $ 87,201 $ 94,290
Schedule of reconciliation of goodwill	(in thousands) Balance as of December 31, 2016 $ 643,474 Add: foreign currency translation 710 Balance as of June 30, 2017 $ 644,184

STOCKHOLDERS'_OWNERS' EQUITY (T

STOCKHOLDERS'/OWNERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of accumulated other comprehensive loss	Omega As of and For the Three As of and For the Six 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (50,614 ) $ (13,143 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,195 (21,836 ) 14,468 (26,544 ) Realized gain (loss) 79 - 140 (22 ) Ending balance (40,340 ) (34,979 ) (40,340 ) (34,979 ) Derivative Instruments: Cash flow hedges: Beginning balance (166 ) (9,594 ) (1,420 ) (718 ) Unrealized loss (1,840 ) (4,198 ) (1,350 ) (13,074 ) Realized gain 626 - 1,390 - Ending balance (1,380 ) (13,792 ) (1,380 ) (13,792 ) Net investment hedge: Beginning balance - - - - Unrealized loss (2,193 ) - (2,193 ) - Ending balance (2,193 ) - (2,193 ) - Total accumulated other comprehensive loss (43,913 ) (48,771 ) (43,913 ) (48,771 ) Add: portion included in noncontrolling interest 2,010 2,308 2,010 2,308 Total accumulated other comprehensive loss $ (41,903 ) $ (46,463 ) $ (41,903 ) $ (46,463 ) OHI Holdco As of and For the Three As of and For the Six 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (50,614 ) $ (13,143 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,195 (21,836 ) 14,468 (26,544 ) Realized gain (loss) 79 - 140 (22 ) Ending balance (40,340 ) (34,979 ) (40,340 ) (34,979 ) Derivative Instruments: Cash flow hedges: Beginning balance (166 ) (9,594 ) (1,420 ) (718 ) Unrealized loss (1,840 ) (4,198 ) (1,350 ) (13,074 ) Realized gain 626 - 1,390 - Ending balance (1,380 ) (13,792 ) (1,380 ) (13,792 ) Net investment hedge: Beginning balance - - - - Unrealized loss (2,193 ) - (2,193 ) - Ending balance (2,193 ) - (2,193 ) - Total accumulated other comprehensive loss (43,913 ) (48,771 ) (43,913 ) (48,771 ) Add: portion included in noncontrolling interest 34,116 37,965 34,116 37,965 Total accumulated other comprehensive loss $ (9,797 ) $ (10,806 ) $ (9,797 ) $ (10,806 ) Omega OP As of and For the Three As of and For the Six 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (50,614 ) $ (13,143 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,195 (21,836 ) 14,468 (26,544 ) Realized gain (loss) 79 - 140 (22 ) Ending balance (40,340 ) (34,979 ) (40,340 ) (34,979 ) Derivative Instruments: Cash flow hedges: Beginning balance (166 ) (9,594 ) (1,420 ) (718 ) Unrealized loss (1,840 ) (4,198 ) (1,350 ) (13,074 ) Realized gain 626 - 1,390 - Ending balance (1,380 ) (13,792 ) (1,380 ) (13,792 ) Net investment hedge: Beginning balance - - - - Unrealized loss (2,193 ) - (2,193 ) - Ending balance (2,193 ) - (2,193 ) - Total accumulated other comprehensive loss $ (43,913 ) $ (48,771 ) $ (43,913 ) $ (48,771 )

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of stock-based compensation expense	Three Months Ended Six Months Ended June 30, 2017 2016 2017 2016 (in thousands) Stock-based compensation expense $ 3,734 $ 3,665 $ 7,478 $ 6,443
Schedule of unrecognized compensation cost associated with outstanding restricted stock and PRSU awards and LTIP Unit awards	Grant Shares/ Units Grant Date Total (1) Weighted Unrecognized Performance Vesting RSUs 3/31/15 RSU 2015 109,985 $ 40.57 $ 4.5 33 $ 0.8 N/A 12/31/2017 4/1/15 RSU 2015 40,464 40.74 1.6 33 0.3 N/A 12/31/2017 Assumed Aviv RSU 2015 7,799 35.08 0.3 33 0.1 N/A 11/1/2017 3/17/16 RSU 2016 130,006 34.78 4.6 33 2.4 N/A 12/31/2018 1/1/2017 RSU 2017 140,416 31.26 4.3 36 3.6 N/A 12/31/2019 Restricted Stock Units Total 428,670 $ 35.68 $ 15.3 $ 7.2 TSR PRSUs and LTIP Units 2016 TSR 2014 135,634 $ 8.67 $ 1.2 48 $ 0.2 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 LTIP Units 2015 137,249 14.66 2.0 45 0.8 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 LTIP Units 2015 54,151 14.80 0.8 45 0.3 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 LTIP Units 2016 372,069 13.21 4.9 45 3.2 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 LTIP Units 2017 399,726 12.61 5.0 48 4.4 1/1/2017-12/31/2019 Quarterly in 2020 TSR PRSUs & LTIP Total 1,098,829 $ 12.69 $ 13.9 $ 8.9 Relative TSR PRSUs 2016 Relative TSR 2014 135,634 $ 14.24 $ 1.9 48 $ 0.2 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 Relative TSR 2015 137,249 22.50 3.1 45 1.2 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 Relative TSR 2015 54,151 22.91 1.2 45 0.5 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 Relative TSR 2016 307,480 16.45 5.1 45 3.4 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 Relative TSR 2017 285,338 18.04 5.1 48 4.5 1/1/2017-12/31/2019 Quarterly in 2020 Relative TSR PRSUs Total 919,852 $ 17.78 $ 16.4 $ 9.8 Grand Total 2,447,351 $ 18.63 $ 45.6 $ 25.9 (1) Total compensation costs are net of shares cancelled.

BORROWING ACTIVITIES AND ARRA35

BORROWING ACTIVITIES AND ARRANGEMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of borrowings	Annual Interest June 30, June 30, December 31, Maturity 2017 2017 2016 (in thousands) Secured borrowings: HUD mortgages assumed December 2011 (1) 2044 3.06% $ 54,316 $ 54,954 Deferred financing costs – net (579 ) (589 ) Total secured borrowings – net (2) 53,737 54,365 Unsecured borrowings: Revolving line of credit 2021 2.47% 155,000 190,000 Tranche A-1 term loan - - — 200,000 Tranche A-2 term loan - - — 200,000 Tranche A-3 term loan - - — 350,000 U.S. term loan 2022 2.67% 425,000 — Sterling term loan 2022 1.70% 130,250 — Omega OP term loan (2) 2022 2.67% 100,000 100,000 2015 term loan 2022 3.80% 250,000 250,000 Discounts and deferred financing costs – net (3) (5,958 ) (5,657 ) Total term loans – net 899,292 1,094,343 2023 notes 2023 4.375% 700,000 700,000 2024 notes 2024 5.875% — 400,000 2024 notes 2024 4.95% 400,000 400,000 2025 notes 2025 4.50% 400,000 250,000 2026 notes 2026 5.25% 600,000 600,000 2027 notes 2027 4.50% 700,000 700,000 2028 notes 2028 4.75% 550,000 — Other 2018 - 1,500 3,000 Subordinated debt 2021 9.00% 20,000 20,000 Discount - net (22,345 ) (17,151 ) Deferred financing costs – net (27,297 ) (27,703 ) Total unsecured borrowings – net 3,321,858 3,028,146 Total secured and unsecured borrowings – net $ 4,429,887 $ 4,366,854 (1) Reflects the weighted average annual contractual interest rate on the mortgages at June 30, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $63.9 million as of June 30, 2017. (2) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP. (3) This amount includes $0.6 million of net deferred financing costs related to the Omega OP term loan as of June 30, 2017.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of the carrying amounts and fair values of financial instruments	June 30, 2017 December 31, 2016 Carrying Amount Fair Value Carrying Amount Fair Value (in thousands) Assets: Investments in direct financing leases – net $ 582,307 $ 578,998 $ 601,938 $ 598,665 Mortgage notes receivable – net 662,709 676,396 639,343 644,961 Other investments – net 278,985 271,306 256,846 253,385 Total $ 1,524,001 $ 1,526,700 $ 1,498,127 $ 1,497,011 Liabilities: Revolving line of credit $ 155,000 $ 155,000 $ 190,000 $ 190,000 Tranche A-1 term loan — — 198,830 200,000 Tranche A-2 term loan — — 200,000 200,000 Tranche A-3 term loan — — 347,449 350,000 U.S. term loan 422,280 425,000 — — Sterling term loan 129,413 130,250 — — Omega OP term loan (1) 99,373 100,000 100,000 100,000 2015 term loan 248,226 250,000 248,064 250,000 4.375% notes due 2023 – net 692,890 723,805 692,305 693,505 5.875% notes due 2024 – net — — 395,065 432,938 4.95% notes due 2024 – net 393,175 421,504 392,669 406,361 4.50% notes due 2025 – net 394,368 361,983 245,949 249,075 5.25% notes due 2026 – net 593,969 641,199 593,616 611,461 4.50% notes due 2027 – net 685,784 703,514 685,052 681,978 4.75% notes due 2028 – net 539,741 557,520 — — HUD debt – net (1) 53,737 52,535 54,365 52,510 Subordinated debt – net 20,431 24,045 20,490 23,944 Other 1,500 1,500 3,000 3,000 Total $ 4,429,887 $ 4,547,855 $ 4,366,854 $ 4,444,772 (1) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

EARNINGS PER SHARE_UNIT (Tables

EARNINGS PER SHARE/UNIT (Tables)	6 Months Ended
	Jun. 30, 2017
Net Income Available To Common Per Share
Schedule of computation of basic and diluted earnings per share	Omega Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net income $ 68,157 $ 113,154 $ 177,269 $ 171,350 Less: net income attributable to noncontrolling interests (2,900 ) (5,102 ) (7,572 ) (7,743 ) Net income available to common stockholders $ 65,257 $ 108,052 $ 169,697 $ 163,607 Denominator: Denominator for basic earnings per share 197,433 188,981 197,223 188,604 Effect of dilutive securities: Common stock equivalents 467 1,254 407 1,215 Noncontrolling interest – Omega OP Units 8,772 8,922 8,793 8,935 Denominator for diluted earnings per share 206,672 199,157 206,423 198,754 Earnings per share – basic: Net income available to common stockholders $ 0.33 $ 0.57 $ 0.86 $ 0.87 Earnings per share – diluted: Net income $ 0.33 $ 0.57 $ 0.86 $ 0.86 Omega OP Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net income $ 68,157 $ 113,154 $ 177,269 $ 171,350 Denominator: Denominator for basic earnings per unit 206,205 197,903 206,016 197,539 Effect of dilutive securities: Omega OP Unit equivalents 467 1,254 407 1,215 Denominator for diluted earnings per unit 206,672 199,157 206,423 198,754 Earnings per unit – basic: Net income available to Omega OP Unit holders $ 0.33 $ 0.57 $ 0.86 $ 0.87 Earnings per unit – diluted: Net income $ 0.33 $ 0.57 $ 0.86 $ 0.86

BASIS OF PRESENTATION AND SIG38

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Contractual receivables	$ 40,484	$ 13,376
Effective yield interest receivables	10,940	9,749
Straight-line rent receivables	231,233	208,874
Lease inducements	7,498	8,393
Allowance	(1,469)	(357)
Accounts receivable - net	$ 288,686	$ 240,035

BASIS OF PRESENTATION AND SIG39

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail)	6 Months Ended
	Jun. 30, 2017Segment
Accounting Policies [Abstract]
Number of reportable segment	1

BASIS OF PRESENTATION AND SIG40

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail 1)	Feb. 01, 2016USD ($)Facility	Jun. 30, 2017USD ($)FacilityHealthcare_facility	Mar. 31, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)FacilityHealthcare_facility	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Impairment losses recognized		$ 10,135,000	$ 7,600,000	$ 6,893,000	$ 17,773,000	$ 41,451,000
Number of leased real estate properties | Healthcare_facility		999			999
SNF's
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of leased real estate properties | Facility		803			803
Cash flow hedges
Basis Of Presentation And Significant Accounting Policies [Line Items]
Cash flow hedges recorded at fair value in accrued expenses and other liabilities		$ 1,400,000			$ 1,400,000		$ 1,500,000
Omega OP Units
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned		96.00%			96.00%
Other Investors | Omega OP Units
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned		4.00%			4.00%
Laurel | SNF's
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of leased real estate properties | Facility	10
Purchase price of buildings acquired paid in cash	$ 169,000,000
Percentage of ownership interest	34.00%

PROPERTIES AND INVESTMENTS - In

PROPERTIES AND INVESTMENTS - Investment in leased real estate properties (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 7,730,199	$ 7,566,358
Less accumulated depreciation	(1,366,376)	(1,240,336)
Real estate investments - net	6,363,823	6,326,022
Buildings
Property, Plant and Equipment [Line Items]
Total real estate investments	6,055,423	5,954,771
Land
Property, Plant and Equipment [Line Items]
Total real estate investments	796,561	759,295
Furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total real estate investments	458,427	454,760
Site improvements
Property, Plant and Equipment [Line Items]
Total real estate investments	204,993	206,206
Construction in progress
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 214,795	$ 191,326

PROPERTIES AND INVESTMENTS - Si

PROPERTIES AND INVESTMENTS - Significant acquisitions that occurred during the first six months of 2017 (Detail 1) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)FacilityHealthcare_facility
Real Estate Properties [Line Items]
Number of Facilities | Healthcare_facility	999
SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	803
ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	119
2017 acquisitions and other
Real Estate Properties [Line Items]
Total Investment	$ 140.4
2017 acquisitions and other | Land
Real Estate Properties [Line Items]
Total Investment	35.3
2017 acquisitions and other | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	99.2
2017 acquisitions and other | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	$ 5.9
2017 acquisitions and other | SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	1
2017 acquisitions and other | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	19
2017 acquisitions and other | Q1 | VA
Real Estate Properties [Line Items]
Total Investment	$ 7.6
Initial Annual Cash Yield (%)	7.50%	[1]
2017 acquisitions and other | Q1 | VA | Land
Real Estate Properties [Line Items]
Total Investment	$ 0.5
2017 acquisitions and other | Q1 | VA | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	6.8
2017 acquisitions and other | Q1 | VA | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	$ 0.3
2017 acquisitions and other | Q1 | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	1
2017 acquisitions and other | Q2 | NC
Real Estate Properties [Line Items]
Total Investment	$ 8.6
Initial Annual Cash Yield (%)	9.50%	[1]
2017 acquisitions and other | Q2 | NC | Land
Real Estate Properties [Line Items]
Total Investment	$ 0.7
2017 acquisitions and other | Q2 | NC | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	7.3
2017 acquisitions and other | Q2 | NC | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	0.6
2017 acquisitions and other | Q2 | UK
Real Estate Properties [Line Items]
Total Investment	$ 124.2	[2]
Initial Annual Cash Yield (%)	8.50%	[1]
2017 acquisitions and other | Q2 | UK | Land
Real Estate Properties [Line Items]
Total Investment	$ 34.1
2017 acquisitions and other | Q2 | UK | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	85.1
2017 acquisitions and other | Q2 | UK | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	$ 5
2017 acquisitions and other | Q2 | SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	1
2017 acquisitions and other | Q2 | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	18
[1]	The cash yield is based on the purchase price.
[2]	Omega recorded a non-cash deferred tax liability and acquisitions costs of approximately $8.2 million and $1.2 million, respectively, in connection with this acquisition.

PROPERTIES AND INVESTMENTS (Par

PROPERTIES AND INVESTMENTS (Parentheticals) (Detail 1) - 2017 acquisitions and other - Q2 - UK $ in Millions	Jun. 30, 2017USD ($)
Real Estate Properties [Line Items]
Deferred tax liability	$ 8.2
Acquisitions costs	$ 1.2

PROPERTIES AND INVESTMENTS - Le

PROPERTIES AND INVESTMENTS - Leased Property (Narrative) (Detail) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017USD ($)FacilityHealthcare_facilityParcel	Jun. 30, 2017FacilityHealthcare_facility
Real Estate Properties [Line Items]
Number of real estate properties | Healthcare_facility	999	999
Property available for operating lease | Minimum
Real Estate Properties [Line Items]
Lease term		5 years
Increase in the specific annual percentage over the prior year's rent		2.00%
Property available for operating lease | Maximum
Real Estate Properties [Line Items]
Lease term		15 years
Increase in the specific annual percentage over the prior year's rent		3.00%
SNF's
Real Estate Properties [Line Items]
Number of real estate properties	803	803
ALFs
Real Estate Properties [Line Items]
Number of real estate properties	119	119
Specialty facilities
Real Estate Properties [Line Items]
Number of real estate properties	16	16
Medical office building
Real Estate Properties [Line Items]
Number of real estate properties	1	1
2017 acquisitions and other | SNF's
Real Estate Properties [Line Items]
Number of real estate properties	1	1
2017 acquisitions and other | ALFs
Real Estate Properties [Line Items]
Number of real estate properties	19	19
2017 acquisitions and other | Land
Real Estate Properties [Line Items]
Number of properties acquired | Parcel	2
Cash payment to acquire facilities | $	$ 5.5

PROPERTIES AND INVESTMENTS - As

PROPERTIES AND INVESTMENTS - Assets Sold or Held for Sale (Narrative) (Detail 1) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2017USD ($)Facility	Mar. 31, 2017USD ($)Facility	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)Facility	Jun. 30, 2016USD ($)
Real Estate [Abstract]
Number of facilities sold	3	15		3
Total cash proceeds | $	$ 18,300	$ 45,800
Amount of gain (loss) from sale of facilities | $	$ (600)	$ 7,400
Number of previously classified as held for sale	2	11		2
Provision for impairment on real estate properties | $	$ 10,135	$ 7,600	$ 6,893	$ 17,773	$ 41,451
Number of facilities with impairment charges	6	3		6
Number of facilities with impairment charges classified as held for sale		1

DIRECT FINANCING LEASES (Detail

DIRECT FINANCING LEASES (Detail) $ in Thousands	Jun. 30, 2017USD ($)Lease	Dec. 31, 2016USD ($)Lease
Leases, Capital [Abstract]
Minimum lease payments receivable	$ 4,085,493	$ 4,287,069
Less unearned income	(3,499,877)	(3,685,131)
Less allowance for loss on direct financing lease	(3,309)
Investment in direct financing leases - net	$ 582,307	$ 601,938
Properties subject to direct financing leases | Lease	53	58

DIRECT FINANCING LEASES (Deta47

DIRECT FINANCING LEASES (Detail 1) $ in Thousands	Jun. 30, 2017USD ($)
Leases, Capital [Abstract]
2,017	$ 24,407
2,018	50,019
2,019	51,246
2,020	52,493
2,021	53,681
2,022	$ 55,008

DIRECT FINANCING LEASES (Narrat

DIRECT FINANCING LEASES (Narrative) (Detail) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Nov. 27, 2013USD ($)FacilityLeaseState	Jun. 30, 2017USD ($)FacilityHealthcare_facilityState	Mar. 31, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)FacilityHealthcare_facilityState	Jun. 30, 2016USD ($)
Capital Leased Assets [Line Items]
Number of facilities owned | Healthcare_facility		999			999
Number of states | State		42			42
Income from direct financing leases | $		$ 15,462		$ 15,521	$ 31,108	$ 30,963
Northwest | Direct financing leases | Sales Agreement
Capital Leased Assets [Line Items]
Carrying amount of facility | $			$ 36,400
Estimated sell price | $			34,000
Proceeds from sale of facility | $		27,300
Allowance for loss under direct financing leases | $		900	$ 2,400
Income from direct financing leases | $		$ 500			$ 1,300
New Ark Investment Inc.
Capital Leased Assets [Line Items]
Purchase price of beds acquired paid in cash | $	$ 529,000
Number of lease | Lease	4
Master lease term	50 years
Interest on lease per annum	10.60%
Number of facilities owned	56	50			50
Number of states | State	10
New Ark Investment Inc. | Southeast
Capital Leased Assets [Line Items]
Number of additional facility owned	38
New Ark Investment Inc. | Northwest
Capital Leased Assets [Line Items]
Number of additional facility owned	2
Number of facilities sold		5			5
New Ark Investment Inc. | Texas
Capital Leased Assets [Line Items]
Number of additional facility owned	9
New Ark Investment Inc. | Indiana
Capital Leased Assets [Line Items]
Number of additional facility owned	1
SNF's | New Ark Investment Inc. | Direct financing leases
Capital Leased Assets [Line Items]
Number of facilities owned	55
ALFs | New Ark Investment Inc. | Direct financing leases
Capital Leased Assets [Line Items]
Number of facilities owned	1

MORTGAGE NOTES RECEIVABLE (Deta

MORTGAGE NOTES RECEIVABLE (Details) - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2017	Dec. 31, 2016
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 667,456	$ 643,277
Allowance for loss on mortgage notes receivable		(4,747)	(3,934)
Total mortgages - net		662,709	639,343
Mortgage note due 2024; interest at 9.98%
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 112,500	$ 112,500
Mortgage loans on real estate, interest rate		9.98%	9.98%
Mortgage note due 2029; interest at 9.45%
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 411,467	$ 412,140
Mortgage loans on real estate, interest rate		9.45%	9.45%
Other mortgage notes outstanding
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross	[1]	$ 143,489	$ 118,637
[1]	Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 14.0% and maturity dates through 2029.

MORTGAGE NOTES RECEIVABLE (Pare

MORTGAGE NOTES RECEIVABLE (Parentheticals) (Details) - Other mortgage notes outstanding	6 Months Ended
	Jun. 30, 2017
Minimum
Mortgage Loans on Real Estate [Line Items]
Mortgage loans on real estate, interest rate	8.35%
Maximum
Mortgage Loans on Real Estate [Line Items]
Mortgage loans on real estate, interest rate	14.00%
Maturity year	2,029

MORTGAGE NOTES RECEIVABLE (Narr

MORTGAGE NOTES RECEIVABLE (Narrative) (Detail)	6 Months Ended
	Jun. 30, 2017FacilityStateMortgageEntity
Mortgage Loans on Real Estate [Line Items]
Number of states	42
Mortgage loans
Mortgage Loans on Real Estate [Line Items]
Number of fixed rate mortgages | Mortgage	29
Number of long term care facilities | Facility	52
Number of states	10
Number of independent healthcare operating companies | Entity	7

OTHER INVESTMENTS (Details)

OTHER INVESTMENTS (Details) - USD ($) $ in Thousands		Jun. 30, 2017	Dec. 31, 2016
Schedule of Investments [Line Items]
Other investments, gross		$ 283,783	$ 261,644
Allowance for loss on other investments		(4,798)	(4,798)
Total other investments		278,985	256,846
Other investment note due 2019; interest at 10.96%
Schedule of Investments [Line Items]
Other investments, gross		$ 49,583	$ 49,458
Interest rate		10.96%	10.96%
Other investment note due 2020; interest at 14.00%
Schedule of Investments [Line Items]
Other investments, gross		$ 47,899	$ 47,913
Interest rate		14.00%	14.00%
Other investment note due 2022, interest at 9.00%
Schedule of Investments [Line Items]
Other investments, gross		$ 31,987	$ 31,987
Interest rate		9.00%	9.00%
Other investment note due 2030; interest at 6.66%
Schedule of Investments [Line Items]
Other investments, gross		$ 50,000	$ 44,595
Interest rate		6.66%	6.66%
Other investment notes outstanding
Schedule of Investments [Line Items]
Other investments, gross	[1]	$ 104,314	$ 87,691
[1]	Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

OTHER INVESTMENTS (Parenthetica

OTHER INVESTMENTS (Parentheticals) (Details) - Other investment notes outstanding	6 Months Ended
	Jun. 30, 2017
Minimum
Schedule of Investments [Line Items]
Interest rate	6.50%
Maximum
Schedule of Investments [Line Items]
Interest rate	13.00%
Maturity year	2,028

INVESTMENT IN UNCONSOLIDATED 54

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE (Details) $ in Thousands	Nov. 01, 2016USD ($)Facility	Jun. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated joint venture		$ 38,968	$ 38,968	$ 48,776
Assets management fees recognized		$ 500	$ 1,000
Second Spring Healthcare Investments
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated joint venture	$ 50,000
Percentage of ownership interest	15.00%
Second Spring Healthcare Investments | Affiliates of Lindsey Goldberg LLC
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest	85.00%
Second Spring Healthcare Investments | Welltower Inc | SNF's
Schedule of Equity Method Investments [Line Items]
Number of properties acquired | Facility	64
Payments to acquire facilities	$ 1,100,000

ASSETS HELD FOR SALE (Details)

ASSETS HELD FOR SALE (Details) $ in Thousands		3 Months Ended
		Jun. 30, 2017USD ($)Property		Mar. 31, 2017USD ($)Property
Number Of Properties
Beginning Balance | Property		9		20
Properties sold/other | Property	[1]	(2)		(12)
Properties added | Property	[2]			1
Ending balance | Property		7	[3]	9
Net Book Value
Beginning Balance | $		$ 23,245		$ 52,868
Properties sold/other | $	[1]	(4,356)		(30,023)
Properties added | $	[2]			400
Ending balance | $		$ 18,889	[3]	$ 23,245
[1]	In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility's then carrying value adjusted for depreciation that was not recognized while classified as held for sale. In the second quarter of 2017, we sold one ALF and one SNF for approximately $5.0 million in net proceeds, generating a gain on sale of approximately $0.6 million.
[2]	In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF's net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale.
[3]	We plan to sell the facilities classified as held for sale at June 30, 2017 within the next twelve months.

ASSETS HELD FOR SALE (Parenthet

ASSETS HELD FOR SALE (Parentheticals) (Details) $ in Millions	3 Months Ended
	Jun. 30, 2017USD ($)Facility	Mar. 31, 2017USD ($)FacilityProperty
Real Estate Properties [Line Items]
Net proceeds from sale of facilities held for sale | $	$ 5	$ 29.4
Gain (loss) from sale of facilities | $	$ (0.6)	$ 3.6
Number of facilities with impairment charges | Facility		1
SNF's
Real Estate Properties [Line Items]
Number of facilities held for sale sold | Facility	1	9
Number of property reclassified | Property		1
Carrying value for property reclassified | $		$ 5.1
ALFs
Real Estate Properties [Line Items]
Number of facilities held for sale sold | Facility	1	2
Impairment charges | $		$ 3.5
Number of facilities with impairment charges | Facility		1

INTANGIBLES - Summary of our in

INTANGIBLES - Summary of our intangibles (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets:
Goodwill	$ 644,184	$ 643,474
Accumulated amortization	(16,477)	(15,864)
Net intangible assets	6,116	6,779
Liabilities:
Below market leases	164,735	165,028
Accumulated amortization	(77,534)	(70,738)
Net intangible liabilities	87,201	94,290
Above market leases
Assets:
Gross intangible assets	22,426	22,476
In-place leases
Assets:
Gross intangible assets	$ 167	$ 167

INTANGIBLES - Reconciliation of

INTANGIBLES - Reconciliation of goodwill (Details 1) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Goodwill [Roll Forward]
Balance	$ 643,474
Add: foreign currency translation	710
Balance	$ 644,184

INTANGIBLES (Narrative) (Detail

INTANGIBLES (Narrative) (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 3.1	$ 3.6	$ 6.2	$ 7.9
Remainder of 2017	5.8		5.8
2,018	10.5		10.5
2,019	9.5		9.5
2,020	9.3		9.3
2,021	$ 8.7		$ 8.7

INTANGIBLES (Narrative) (Deta60

INTANGIBLES (Narrative) (Detail 1)	6 Months Ended
	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Below market leases, weighted average remaining amortization	9 years
Above market lease intangibles
Finite-Lived Intangible Assets [Line Items]
Weighted average remaining amortization	8 years

CONCENTRATION OF RISK (Narrativ

CONCENTRATION OF RISK (Narrative) (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)FacilityHealthcare_facilityStateOperator	Dec. 31, 2016USD ($)
Concentration Risk [Line Items]
Number of facilities owned | Healthcare_facility	999
Number of states | State	42
Number of operators | Operator	77
Gross investment in facilities, net of impairments and before reserve for uncollectible loans | $	$ 9,000,000
Investment in an unconsolidated joint venture | $	$ 39,000
Percentage share of real estate investments related to long-term care facilities	99.00%
Number of facilities held-for-sale/closed	9
Other investments | $	$ 278,985	$ 256,846
Concentration risk, benchmark description	No single operator or manager generated more than 10% of our total revenues for the six months ended June 30, 2017.
Ohio
Concentration Risk [Line Items]
Concentration percent by state	9.00%
Texas
Concentration Risk [Line Items]
Concentration percent by state	9.00%
Florida
Concentration Risk [Line Items]
Concentration percent by state	9.00%
SNF's
Concentration Risk [Line Items]
Number of facilities owned	803
Number of facilities under fixed rate mortgage loan	47
ALFs
Concentration Risk [Line Items]
Number of facilities owned	119
Number of facilities under fixed rate mortgage loan	4
Specialty facilities
Concentration Risk [Line Items]
Number of facilities owned	16
Medical office building
Concentration Risk [Line Items]
Number of facilities owned	1
Ciena Healthcare
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%

STOCKHOLDERS'_OWNERS' EQUITY (D

STOCKHOLDERS'/OWNERS' EQUITY (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Cumulative Translation Adjustment Summary [Roll Forward]
Total accumulated other comprehensive loss	$ (43,913)	$ (48,771)	$ (43,913)	$ (48,771)
Add: portion included in noncontrolling interest	2,010	2,308	2,010	2,308
Total accumulated other comprehensive loss	(41,903)	(46,463)	(41,903)	(46,463)	$ (53,827)
OHI Holdco
Cumulative Translation Adjustment Summary [Roll Forward]
Total accumulated other comprehensive loss	(43,913)	(48,771)	(43,913)	(48,771)
Add: portion included in noncontrolling interest	34,116	37,965	34,116	37,965
Total accumulated other comprehensive loss	(9,797)	(10,806)	(9,797)	(10,806)	$ (12,439)
Omega OP
Cumulative Translation Adjustment Summary [Roll Forward]
Total accumulated other comprehensive loss	(43,913)	(48,771)	(43,913)	(48,771)
Foreign Currency Translation
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(50,614)	(13,143)	(54,948)	(8,413)
Translation gain (loss)	10,195	(21,836)	14,468	(26,544)
Realized gain (loss)	79		140	(22)
Ending balance	(40,340)	(34,979)	(40,340)	(34,979)
Foreign Currency Translation | OHI Holdco
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(50,614)	(13,143)	(54,948)	(8,413)
Translation gain (loss)	10,195	(21,836)	14,468	(26,544)
Realized gain (loss)	79		140	22
Ending balance	(40,340)	(34,979)	(40,340)	(34,979)
Foreign Currency Translation | Omega OP
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(50,614)	(13,143)	(54,948)	(8,413)
Translation gain (loss)	10,195	(21,836)	14,468	(26,544)
Realized gain (loss)	79		140	(22)
Ending balance	(40,340)	(34,979)	(40,340)	(34,979)
Derivative Instruments
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(166)	(9,594)	(1,420)	(718)
Unrealized loss	(1,840)	(4,198)	(1,350)	(13,074)
Realized gain (loss)	626		1,390
Ending balance	(1,380)	(13,792)	(1,380)	(13,792)
Derivative Instruments | OHI Holdco
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(166)	(9,594)	(1,420)	(718)
Unrealized loss	(1,840)	(4,198)	(1,350)	(13,074)
Realized gain (loss)	626		1,390
Ending balance	(1,380)	(13,792)	(1,380)	(13,792)
Derivative Instruments | Omega OP
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(166)	(9,594)	(1,420)	(718)
Translation gain (loss)	(1,840)		(1,350)
Unrealized loss		(4,198)		(13,074)
Realized gain (loss)	626		1,390
Ending balance	(1,380)	(13,792)	(1,380)	(13,792)
Net investment hedge
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance
Unrealized loss	(2,193)		(2,193)
Ending balance	(2,193)		(2,193)
Net investment hedge | OHI Holdco
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance
Unrealized loss	(2,193)		(2,193)
Ending balance	(2,193)		(2,193)
Net investment hedge | Omega OP
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance
Unrealized loss	(2,193)		(2,193)
Ending balance	$ (2,193)		$ (2,193)

STOCKHOLDERS'_OWNERS' EQUITY (N

STOCKHOLDERS'/OWNERS' EQUITY (Narrative) (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 13, 2017	Apr. 13, 2017	Jan. 12, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Dividend [Line Items]
Dividends declared per common share				$ 0.63	$ 0.58	$ 1.25	$ 1.15
Issuance of common stock (in shares)						228,000
Dividend reinvestment plan (in shares)						614,000
Gross proceeds from issuance of common stock						$ 6,634	$ 487
Board of Directors
Dividend [Line Items]
Dividends declared per common share		$ 0.63	$ 0.62
Nature of common stock dividend payable		Quarterly	Quarterly
Increasing the quarterly common dividend		0.01	0.01
Dividends declared, date of declaration		Apr. 13, 2017	Jan. 12, 2017
Dividends declared, date of payment		May 15, 2017	Feb. 15, 2017
Dividends declared, date of record		May 1, 2017	Jan. 31, 2017
500 Million Equity Shelf Program
Dividend [Line Items]
Issuance of common stock (in shares)						200,000
Issuance of common stock, average price per share						$ 29.17
Gross proceeds from issuance of common stock						$ 6,600
Sales price, equity distribution agreement				$ 500,000		$ 500,000
Dividend Reinvestment and Common Stock Purchase Plan
Dividend [Line Items]
Issuance of common stock (in shares)				400,000		614,000
Issuance of common stock, average price per share				$ 33.02		$ 32.11
Gross proceeds from issuance of common stock				$ 12,400		$ 19,700
Subsequent Event | Board of Directors
Dividend [Line Items]
Dividends declared per common share	$ 0.64
Nature of common stock dividend payable	Quarterly
Increasing the quarterly common dividend	0.01
Dividends declared, date of declaration	Jul. 13, 2017
Dividends declared, date of payment	Aug. 15, 2017
Dividends declared, date of record	Aug. 1, 2017

TAXES (Narrative) (Detail)

TAXES (Narrative) (Detail) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2017USD ($)
Income Tax Disclosure [Abstract]
Percentage of minimum taxable income is distributed	90.00%	90.00%
Permitted ownership of a taxable REIT subsidiary ("TRS"), maximum percentage	100.00%	100.00%
Net operating loss carry-forward	$ 0.8	$ 0.8
State and local income tax provision	0.5	1.5
Provision (benefit) for foreign income taxes	$ 0.1	$ 0.2

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock-based compensation expense	$ 3,734	$ 3,665	$ 7,478	$ 6,443

STOCK-BASED COMPENSATION (Det66

STOCK-BASED COMPENSATION (Details 1) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	2,447,351
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 18.63
Total Compensation Cost	$ 45.6	[1]
Unrecognized Compensation Cost	$ 25.9
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	428,670
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 35.68
Total Compensation Cost	$ 15.3	[1]
Unrecognized Compensation Cost	$ 7.2
RSUs | 3/31/15 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	109,985
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 40.57
Total Compensation Cost	$ 4.5	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 0.8
Vesting Dates	12/31/2017
RSUs | 4/1/15 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	40,464
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 40.74
Total Compensation Cost	$ 1.6	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 0.3
Vesting Dates	12/31/2017
RSUs | Assumed Aviv RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	7,799
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 35.08
Total Compensation Cost	$ 0.3	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 0.1
Vesting Dates	11/1/2017
RSUs | 3/17/16 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,016
Shares/Units | shares	130,006
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 34.78
Total Compensation Cost	$ 4.6	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 2.4
Vesting Dates	12/31/2018
RSUs | 1/1/2017 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,017
Shares/Units | shares	140,416
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 31.26
Total Compensation Cost	$ 4.3	[1]
Weighted Average Period of Expense Recognition	36 months
Unrecognized Compensation Cost	$ 3.6
Vesting Dates	12/31/2019
TSR PRSUs and LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	1,098,829
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 12.69
Total Compensation Cost	$ 13.9	[1]
Unrecognized Compensation Cost	$ 8.9
TSR PRSUs and LTIP Units | 2016 TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,014
Shares/Units | shares	135,634
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 8.67
Total Compensation Cost	$ 1.2	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 0.2
Performance Period	1/1/2014-12/31/2016
Vesting Dates	Quarterly in 2017
TSR PRSUs and LTIP Units | 3/31/15 2017 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	137,249
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.66
Total Compensation Cost	$ 2	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.8
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
TSR PRSUs and LTIP Units | 4/1/2015 2017 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	54,151
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.80
Total Compensation Cost	$ 0.8	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.3
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
TSR PRSUs and LTIP Units | 3/17/16 2018 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,016
Shares/Units | shares	372,069
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 13.21
Total Compensation Cost	$ 4.9	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 3.2
Performance Period	1/1/2016-12/31/2018
Vesting Dates	Quarterly in 2019
TSR PRSUs and LTIP Units | 1/1/2017 2019 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,017
Shares/Units | shares	399,726
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 12.61
Total Compensation Cost	$ 5	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 4.4
Performance Period	1/1/2017-12/31/2019
Vesting Dates	Quarterly in 2020
Relative TSR PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	919,852
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 17.78
Total Compensation Cost	$ 16.4	[1]
Unrecognized Compensation Cost	$ 9.8
Relative TSR PRSUs | 2016 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,014
Shares/Units | shares	135,634
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.24
Total Compensation Cost	$ 1.9	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 0.2
Performance Period	1/1/2014-12/31/2016
Vesting Dates	Quarterly in 2017
Relative TSR PRSUs | 3/31/15 2017 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	137,249
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 22.50
Total Compensation Cost	$ 3.1	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 1.2
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
Relative TSR PRSUs | 4/1/2015 2017 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	54,151
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 22.91
Total Compensation Cost	$ 1.2	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.5
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
Relative TSR PRSUs | 3/17/16 2018 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,016
Shares/Units | shares	307,480
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 16.45
Total Compensation Cost	$ 5.1	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 3.4
Performance Period	1/1/2016-12/31/2018
Vesting Dates	Quarterly in 2019
Relative TSR PRSUs | 1/1/2017 2019 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,017
Shares/Units | shares	285,338
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 18.04
Total Compensation Cost	$ 5.1	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 4.5
Performance Period	1/1/2017-12/31/2019
Vesting Dates	Quarterly in 2020
[1]	Total compensation costs are net of shares cancelled.

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	2,447,351
Unrecognized compensation cost | $	$ 25.9
Percentage of operating partnership units distributions	10.00%
Restricted stock | Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	90,421
Vesting period, years	3 years
Unrecognized compensation cost | $	$ 2.2
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	428,670
Unrecognized compensation cost | $	$ 7.2
RSUs | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	140,416
LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	1,098,829
Unrecognized compensation cost | $	$ 8.9
LTIP | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	399,726
Relative TSR PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	919,852
Unrecognized compensation cost | $	$ 9.8
Relative TSR PRSUs | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	285,338

BORROWING ACTIVITIES AND ARRA68

BORROWING ACTIVITIES AND ARRANGEMENTS (Details) - USD ($) $ in Thousands		Apr. 04, 2017	Jun. 30, 2017		May 25, 2017	Dec. 31, 2016
Secured borrowings:
Secured borrowings - net			$ 53,737			$ 54,365
Unsecured borrowings:
Revolving line of credit			155,000			190,000
Term loans - net			899,292			1,094,343
Other			278,985			256,846
Total secured and unsecured borrowings - net			4,429,887			4,366,854
Secured Borrowings
Secured borrowings:
Secured borrowings - net	[1]		$ 53,737			54,365
Secured Borrowings | HUD mortgages assumed December 2011
Debt Instrument [Line Items]
Maturity	[2]		2,044
Rate	[2]		3.06%
Secured borrowings:
Secured borrowings - net	[2]		$ 54,316			54,954
Secured Borrowings | Deferred financing costs - net
Secured borrowings:
Deferred financing costs - net			(579)			(589)
Unsecured borrowings
Unsecured borrowings:
Discount - net			(22,345)			(17,151)
Total unsecured borrowings			3,321,858			3,028,146
Unsecured borrowings | Deferred financing costs - net
Unsecured borrowings:
Discounts and deferred financing costs - net	[3]		(5,958)			(5,657)
Deferred financing costs - net			$ (27,297)			(27,703)
Unsecured borrowings | Revolving line of credit
Debt Instrument [Line Items]
Maturity			2,021
Rate			2.47%
Unsecured borrowings:
Revolving line of credit			$ 155,000			190,000
Unsecured borrowings | Tranche A-1 term loan
Unsecured borrowings:
Unsecured borrowing						200,000
Unsecured borrowings | Tranche A-2 term loan
Unsecured borrowings:
Unsecured borrowing						200,000
Unsecured borrowings | Tranche A-3 term loan
Unsecured borrowings:
Unsecured borrowing						350,000
Unsecured borrowings | U.S. Term Loan Facility
Debt Instrument [Line Items]
Maturity			2,022
Rate			2.67%
Unsecured borrowings:
Term loans - net			$ 425,000
Unsecured borrowing
Unsecured borrowings | Sterling Term Loan Facility
Debt Instrument [Line Items]
Maturity			2,022
Rate			1.70%
Unsecured borrowings:
Term loans - net			$ 130,250
Unsecured borrowing
Unsecured borrowings | Omega OP Term loan
Debt Instrument [Line Items]
Maturity	[1]		2,022
Rate	[1]		2.67%
Unsecured borrowings:
Term loans - net			$ 100,000	[1]	$ 100,000	100,000	[1]
Discounts and deferred financing costs - net			$ (600)
Unsecured borrowings | 2015 term loan
Debt Instrument [Line Items]
Maturity			2,022
Rate			3.80%
Unsecured borrowings:
Term loans - net			$ 250,000		$ 250,000	250,000
Unsecured borrowings | 2023 notes
Debt Instrument [Line Items]
Maturity			2,023
Rate			4.375%
Unsecured borrowings:
Aggregate principal amount			$ 700,000			700,000
Unsecured borrowings | 2024 notes
Debt Instrument [Line Items]
Maturity		2,024	2,024
Rate			5.875%
Unsecured borrowings:
Aggregate principal amount		$ 400,000				400,000
Unsecured borrowings | 2024 notes
Debt Instrument [Line Items]
Maturity			2,024
Rate			4.95%
Unsecured borrowings:
Aggregate principal amount			$ 400,000			400,000
Unsecured borrowings | 2025 notes
Debt Instrument [Line Items]
Maturity		2,025	2,025
Rate		99.54%	4.50%
Unsecured borrowings:
Aggregate principal amount		$ 150,000	$ 400,000			250,000
Unsecured borrowings | 2026 notes
Debt Instrument [Line Items]
Maturity			2,026
Rate			5.25%
Unsecured borrowings:
Aggregate principal amount			$ 600,000			600,000
Unsecured borrowings | 2027 notes
Debt Instrument [Line Items]
Maturity			2,027
Rate			4.50%
Unsecured borrowings:
Aggregate principal amount			$ 700,000			700,000
Unsecured borrowings | 2028 notes
Debt Instrument [Line Items]
Maturity		2,028	2,028
Rate		98.978%	4.75%
Unsecured borrowings:
Aggregate principal amount		$ 550,000	$ 550,000
Unsecured borrowings | Other
Debt Instrument [Line Items]
Maturity			2,018
Unsecured borrowings:
Other			$ 1,500			3,000
Unsecured borrowings | Subordinated debt
Debt Instrument [Line Items]
Maturity			2,021
Rate			9.00%
Unsecured borrowings:
Subordinated debt			$ 20,000			$ 20,000
[1]	These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.
[2]	Reflects the weighted average annual contractual interest rate on the mortgages at June 30, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $63.9 million as of June 30, 2017.
[3]	This amount includes $0.6 million of net deferred financing costs related to the Omega OP term loan as of June 30, 2017.

BORROWING ACTIVITIES AND ARRA69

BORROWING ACTIVITIES AND ARRANGEMENTS (Parentheticals) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Secured Borrowings | HUD mortgages assumed December 2011
Debt Instrument [Line Items]
Percentage of third-party administration fee	0.50%
Real estate assets with a net carrying value	$ 63.9
Unsecured borrowings | Omega OP Term loan
Debt Instrument [Line Items]
Discounts and deferred financing costs - net	$ 0.6

BORROWING ACTIVITIES AND ARRA70

BORROWING ACTIVITIES AND ARRANGEMENTS (Narrative) (Detail) $ in Thousands, £ in Millions	Apr. 04, 2017	May 25, 2017USD ($)	Apr. 28, 2017USD ($)	Jun. 30, 2017USD ($)		Jun. 30, 2017USD ($)		Jun. 30, 2016USD ($)	May 25, 2017GBP (£)	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Long-term line of credit				$ 155,000		$ 155,000				$ 190,000
Term loan				899,292		899,292				1,094,343
Repayment of credit facility						852,000		$ 639,000
Unsecured borrowings
Debt Instrument [Line Items]
Net write-offs associated with unamortized deferred financing costs			$ 4,700
Unsecured borrowings | Revolving line of credit
Debt Instrument [Line Items]
Long-term line of credit				155,000		155,000				190,000
Unsecured borrowings | U.S. Term Loan Facility
Debt Instrument [Line Items]
Unsecured borrowing
Term loan				425,000		425,000
Unsecured borrowings | Sterling Term Loan Facility
Debt Instrument [Line Items]
Unsecured borrowing
Term loan				130,250		130,250
Unsecured borrowings | Tranche A-1 term loan
Debt Instrument [Line Items]
Unsecured borrowing										200,000
Unsecured borrowings | Tranche A-2 term loan
Debt Instrument [Line Items]
Unsecured borrowing										200,000
Unsecured borrowings | Tranche A-3 term loan
Debt Instrument [Line Items]
Unsecured borrowing										350,000
Unsecured borrowings | Amended 2015 Term Loan Facility
Debt Instrument [Line Items]
Debt maturity date		Dec. 16, 2022
Term loan		$ 250,000		250,000		250,000				250,000
Credit facility, description of variable rate basis		LIBOR plus an applicable percentage (with a range of 140 to 235 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Maximum aggregate principal amount available under credit facility		$ 150,000
Amount of guaranty of unsecured indebtedness		$ 50,000
Unsecured borrowings | Omega OP Term loan
Debt Instrument [Line Items]
Debt maturity date		May 25, 2022
Term loan		$ 100,000		100,000	[1]	$ 100,000	[1]			$ 100,000	[1]
Credit facility, description of variable rate basis		LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings
Amount of guaranty of unsecured indebtedness		$ 50,000
Unsecured borrowings | 2028 notes
Debt Instrument [Line Items]
Debt maturity date	Jan. 15, 2028
Unsecured borrowings | 2025 notes
Debt Instrument [Line Items]
Debt maturity date	Jan. 15, 2025
Unsecured borrowings | 2024 notes
Debt Instrument [Line Items]
Debt maturity date	Apr. 28, 2017
Unsecured borrowings | Minimum | Omega OP Term loan
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		0.90%
Unsecured borrowings | Maximum | Omega OP Term loan
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		1.90%
Unsecured borrowings | Omega Credit Facilities 2017
Debt Instrument [Line Items]
Long-term line of credit		$ 1,800,000
Maximum borrowing capacity		2,500,000
Net write-offs associated with unamortized deferred financing costs				$ 5,500
Unsecured borrowings | Omega Credit Facilities 2017 | Revolving line of credit
Debt Instrument [Line Items]
Long-term line of credit		1,250,000
Revolving credit facility to be drawn in Alternative Currencies or U.S. Dollars in tranche one		900,000
Revolving credit facility to be drawn in Alternative Currencies or U.S. Dollars in tranche two		$ 350,000
Credit facility, description of variable rate basis		LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Unsecured borrowings | Omega Credit Facilities 2017 | U.S. Term Loan Facility
Debt Instrument [Line Items]
Long-term line of credit		$ 425,000
Unsecured borrowings | Omega Credit Facilities 2017 | Sterling Term Loan Facility
Debt Instrument [Line Items]
Long-term line of credit | £									£ 100
Unsecured borrowings | Omega Credit Facilities 2017 | US And Sterling Term Loan
Debt Instrument [Line Items]
Debt maturity date		May 25, 2022
Credit facility, description of variable rate basis		LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Unsecured borrowings | Omega Credit Facilities 2017 | Tranche A-1 term loan
Debt Instrument [Line Items]
Credit facility terminated		$ 200,000
Unsecured borrowings | Omega Credit Facilities 2017 | Tranche A-2 term loan
Debt Instrument [Line Items]
Credit facility terminated		200,000
Repayment of credit facility		200,000
Unsecured borrowings | Omega Credit Facilities 2017 | Tranche A-3 term loan
Debt Instrument [Line Items]
Credit facility terminated		350,000
Unsecured borrowings | Omega Credit Facilities 2017 | Senior unsecured 2014 revolving credit facility
Debt Instrument [Line Items]
Credit facility terminated		$ 1,250,000
Unsecured borrowings | Omega Credit Facilities 2017 | Minimum | Revolving line of credit
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		1.00%
Unsecured borrowings | Omega Credit Facilities 2017 | Minimum | US And Sterling Term Loan
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		0.90%
Unsecured borrowings | Omega Credit Facilities 2017 | Minimum | Amended 2015 Term Loan Facility
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		1.40%
Unsecured borrowings | Omega Credit Facilities 2017 | Maximum | Revolving line of credit
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		1.95%
Unsecured borrowings | Omega Credit Facilities 2017 | Maximum | US And Sterling Term Loan
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		1.90%
Unsecured borrowings | Omega Credit Facilities 2017 | Maximum | Amended 2015 Term Loan Facility
Debt Instrument [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage		2.35%
[1]	These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

BORROWING ACTIVITIES AND ARRA71

BORROWING ACTIVITIES AND ARRANGEMENTS (Narrative) (Detail 1) - USD ($) $ in Thousands	Apr. 04, 2017	Apr. 28, 2017	Jun. 30, 2017	Dec. 31, 2016
Unsecured borrowings
Debt Instrument [Line Items]
Net proceeds from the offering after deducting underwriting discounts and expenses	$ 690,700
Redemption related costs and write offs		$ 16,500
Call premium		11,800
Net write-offs associated with unamortized deferred financing costs		$ 4,700
4.75% notes due 2028
Debt Instrument [Line Items]
Rate			4.75%
4.75% notes due 2028 | Unsecured borrowings
Debt Instrument [Line Items]
Maturity	2,028		2,028
Rate	4.75%
Aggregate principal amount	$ 550,000		$ 550,000
Maturity date	Jan. 15, 2028
Percentage of notes sold at an issue price	98.978%		4.75%
4.50% notes due 2025
Debt Instrument [Line Items]
Rate			4.50%
4.50% notes due 2025 | Unsecured borrowings
Debt Instrument [Line Items]
Maturity	2,025		2,025
Rate	4.50%
Aggregate principal amount	$ 150,000		$ 400,000	250,000
Maturity date	Jan. 15, 2025
Percentage of notes sold at an issue price	99.54%		4.50%
5.875% notes due 2024
Debt Instrument [Line Items]
Rate			5.875%
5.875% notes due 2024 | Unsecured borrowings
Debt Instrument [Line Items]
Maturity	2,024		2,024
Rate	5.875%
Aggregate principal amount	$ 400,000			$ 400,000
Maturity date	Apr. 28, 2017
Percentage of notes sold at an issue price			5.875%
Tranche A-2 term loan | Unsecured borrowings
Debt Instrument [Line Items]
Prepay senior unsecured incremental term loan facility	$ 200,000

FINANCIAL INSTRUMENTS (Detail)

FINANCIAL INSTRUMENTS (Detail) - USD ($) $ in Thousands		Jun. 30, 2017	Dec. 31, 2016
Assets:
Investments in direct financing leases - net		$ 582,307	$ 601,938
Mortgage notes receivable - net		662,709	639,343
Other investments - net		278,985	256,846
Liabilities:
Revolving line of credit		155,000	190,000
2015 term loan		899,292	1,094,343
HUD debt - net		53,737	54,365
Carrying Amount
Assets:
Investments in direct financing leases - net		582,307	601,938
Mortgage notes receivable - net		662,709	639,343
Other investments - net		278,985	256,846
Total		1,524,001	1,498,127
Liabilities:
Revolving line of credit		155,000	190,000
Tranche A-1 term loan			198,830
Tranche A-2 term loan			200,000
Tranche A-3 term loan			347,449
U.S. term loan		422,280
Sterling term loan		129,413
Omega OP term loan	[1]	99,373	100,000
2015 term loan		248,226	248,064
HUD debt - net	[1]	53,737	54,365
Subordinated debt - net		20,431	20,490
Other		1,500	3,000
Total		4,429,887	4,366,854
Carrying Amount | 4.375% notes due 2023
Liabilities:
Notes Payable		692,890	692,305
Carrying Amount | 5.875% notes due 2024
Liabilities:
Notes Payable			395,065
Carrying Amount | 4.95% notes due 2024
Liabilities:
Notes Payable		393,175	392,669
Carrying Amount | 4.50% notes due 2025
Liabilities:
Notes Payable		394,368	245,949
Carrying Amount | 5.25% notes due 2026
Liabilities:
Notes Payable		593,969	593,616
Carrying Amount | 4.50% notes due 2027
Liabilities:
Notes Payable		685,784	685,052
Carrying Amount | 4.75% notes due 2028
Liabilities:
Notes Payable		539,741
Fair Value
Assets:
Investments in direct financing leases - net		578,998	598,665
Mortgage notes receivable - net		676,396	644,961
Other investments - net		271,306	253,385
Total		1,526,700	1,497,011
Liabilities:
Revolving line of credit		155,000	190,000
Tranche A-1 term loan			200,000
Tranche A-2 term loan			200,000
Tranche A-3 term loan			350,000
U.S. term loan		425,000
Sterling term loan		130,250
Omega OP term loan	[1]	100,000	100,000
2015 Term loan		250,000	250,000
HUD debt - net	[1]	52,535	52,510
Subordinated debt - net		24,045	23,944
Other		1,500	3,000
Total		4,547,855	4,444,772
Fair Value | 4.375% notes due 2023
Liabilities:
Notes Payable		723,805	693,505
Fair Value | 5.875% notes due 2024
Liabilities:
Notes Payable			432,938
Fair Value | 4.95% notes due 2024
Liabilities:
Notes Payable		421,504	406,361
Fair Value | 4.50% notes due 2025
Liabilities:
Notes Payable		361,983	249,075
Fair Value | 5.25% notes due 2026
Liabilities:
Notes Payable		641,199	611,461
Fair Value | 4.50% notes due 2027
Liabilities:
Notes Payable		703,514	681,978
Fair Value | 4.75% notes due 2028
Liabilities:
Notes Payable		$ 557,520
[1]	These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

FINANCIAL INSTRUMENTS (Parenthe

FINANCIAL INSTRUMENTS (Parentheticals) (Detail)	Jun. 30, 2017
4.375% notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.375%
5.875% notes due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	5.875%
4.95% notes due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.95%
4.50% notes due 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.50%
5.25% notes due 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	5.25%
4.50% notes due 2027
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.50%
4.75% notes due 2028
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.75%

EARNINGS PER SHARE_UNIT - Compu

EARNINGS PER SHARE/UNIT - Computation of basic and diluted earnings per share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net income	$ 68,157	$ 113,154	$ 177,269	$ 171,350
Less: net income attributable to noncontrolling interests	(2,900)	(5,102)	(7,572)	(7,743)
Net income available to common stockholders	$ 65,257	$ 108,052	$ 169,697	$ 163,607
Denominator:
Denominator for basic earnings per share	197,433	188,981	197,223	188,604
Effect of dilutive securities:
Common stock equivalents	467	1,254	407	1,215
Noncontrolling interest - Omega OP Units	8,772	8,922	8,793	8,935
Denominator for diluted earnings per share	206,672	199,157	206,423	198,754
Earnings per share - basic:
Net income available to common stockholders (in dollars per share)	$ 0.33	$ 0.57	$ 0.86	$ 0.87
Earnings per share - diluted:
Net income (in dollars per share)	$ 0.33	$ 0.57	$ 0.86	$ 0.86
Omega OP
Numerator:
Net income	$ 68,157	$ 113,154	$ 177,269	$ 171,350
Denominator:
Denominator for basic earnings per unit	206,205	197,903	206,016	197,539
Effect of dilutive securities:
Noncontrolling interest - Omega OP Units	467	1,254	407	1,215
Denominator for diluted earnings per unit	206,672	199,157	206,423	198,754
Earnings per unit - basic:
Net income available to Omega OP Unit holders (in shares)	$ 0.33	$ 0.57	$ 0.86	$ 0.87
Earnings per unit - diluted:
Net income (in dollars per shares)	$ 0.33	$ 0.57	$ 0.86	$ 0.86